Conventional and Neo-Antigenic Peptides Presented by &#946; Cells Are Targeted by Circulating Na&#239;ve CD8+ T Cells in Type 1 Diabetic and Healthy Donors. by Gonzalez-Duque, S et al.
08 January 2022
AperTO - Archivio Istituzionale Open Access dell'Università di Torino
Original Citation:
Conventional and Neo-Antigenic Peptides Presented by  Cells Are Targeted by Circulating Naïve CD8+ T Cells in





(Article begins on next page)
Anyone can freely access the full text of works made available as "Open Access". Works made available under a
Creative Commons license can be used according to the terms and conditions of said license. Use of all other works
requires consent of the right holder (author or publisher) if not exempted from copyright protection by the applicable law.
Availability:
This is a pre print version of the following article:



















SCG5, PCSK2, UCN3, ISL1
INS, CHGA, …
Pancreas CD8+ T cells













 Peptide HLA Class I presentation by β cells is increased by inflammatory cytokines. 
 Peptide sources feature several insulin granule proteins, e.g. SCG5, PCSK2, UCN3. 
 SCG5-009 mRNA splice products and IAPP fusion peptides are also presented. 
 In type 1 diabetes, peptide-reactive CD8+ T cells are enriched in the pancreas. 
 
eTOC BLURB 
The epitopes presented by β cells for recognition by autoimmune CD8+ T lymphocytes remain 
elusive. Gonzalez-Duque et al. identify them as derived from conventional processing, mRNA and 
peptide splicing. They are selectively recognized by CD8+ T lymphocytes of type 1 diabetic 
patients in the pancreas, but not in the blood. 
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Conventional and neo-antigenic peptides presented by β cells are preferentially targeted 
in the pancreas, but not in blood, of type 1 diabetic patients 
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Although CD8+ T-cell-mediated autoimmune β-cell destruction occurs in type 1 diabetes 
(T1D), the target epitopes processed and presented by β cells are unknown. To identify them, 
we combined peptidomics and transcriptomics strategies. Inflammatory cytokines increased 
peptide presentation in vitro, paralleling upregulation of Human Leukocyte Antigen (HLA) 
Class I expression. Peptide sources featured several insulin granule proteins and all known β-
cell antigens, barring islet-specific glucose-6-phosphatase catalytic subunit-related protein. 
Preproinsulin yielded HLA-A2-restricted epitopes previously described. Secretogranin V and 
its mRNA splice isoform SCG5-009, proconvertase-2, urocortin-3, the insulin gene enhancer 
protein ISL-1 and an islet amyloid polypeptide transpeptidation product emerged as antigens 
processed into HLA-A2-restricted epitopes which, as those already described, were 
recognized by circulating naïve CD8+ T cells in T1D and healthy donors, and by pancreas-
infiltrating cells in T1D donors. This peptidome opens new avenues to understand antigen 
processing by β cells and for developing T-cell biomarkers and tolerogenic vaccination 
strategies. 
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Autoimmune CD8+ T cells dominate the pancreatic immune infiltrates of human type 1 
diabetes (T1D) (Coppieters et al., 2012), and lyse β cells by recognizing surface peptide-
Human Leukocyte Antigen Class I (pHLA-I) complexes. Identifying these peptides is 
therefore critical for developing tolerogenic vaccination strategies and immune staging tools 
targeting islet-reactive CD8+ T cells.  
Most islet antigens (Ags), namely insulin (INS) and its precursor preproinsulin (PPI), 
glutamic acid decarboxylase (GAD65/GAD2), islet Ag (IA)-2 (PTPRN) (Mallone et al., 2007; 
Martinuzzi et al., 2008), and zinc transporter 8 (ZnT8/SLC30A8) (Scotto et al., 2012), have 
been identified based on their targeting by auto-antibodies (aAbs). Other Ags such as islet-
specific glucose-6-phosphatase catalytic subunit-related protein (IGRP) (Mallone et al., 
2007), chromogranin A (CHGA) (Li et al., 2015) and islet amyloid polypeptide (IAPP) 
(Standifer et al., 2006) have been identified based on studies in the non-obese diabetic mouse 
and/or their islet-enriched expression. A systematic discovery effort is missing, and the 
available catalogue may be biased by the lack of information about the peptides that are 
naturally processed and presented by β cells.  
Mutated sequences in tumor proteins become preferential CD8+ T-cell targets (Gubin et al., 
2014), possibly because they are regarded as non-self and therefore not efficiently tolerized. 
Similarly, other processes in β cells may facilitate tolerance escape: post-translational 
modifications (PTMs) (McGinty et al., 2014; Rondas et al., 2015), transpeptidation, i.e. the 
splicing and fusion of non-contiguous peptide fragments from the same protein or from 
different ones (Babon et al., 2016; Delong et al., 2016), and the use of alternative transcription 
start sites (Kracht et al., 2017). These studies have mostly focused on CD4+ T cells, which are 
stimulated by pHLA Class II complexes presented by professional Ag-presenting cells that 
uptake β-cell material. These indirect Ag processing pathways do not reflect those that are 
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specific to β cells. Indeed, several arguments suggest an active role of β cells in their own 
demise (Eizirik et al., 2009). 
First, we recently showed that some T1D susceptibility gene variants modulate islet 
inflammation (Marroqui et al., 2015; Marroqui et al., 2014; Moore et al., 2009), suggesting 
that the β-cell response to inflammation is genetically modulated. This response triggers 
cytokine/chemokine release, endoplasmic reticulum (ER) stress and HLA-I upregulation 
(Eizirik et al., 2009; Marroqui et al., 2017), which facilitate a productive autoimmune 
response. The alternative mRNA splicing signature induced by β-cell inflammation (Eizirik et 
al., 2012; Ortis et al., 2010) has received less attention, but may similarly generate neo-
sequences not translated in the thymus and regarded as non-self. 
Second, we recently reported a circulating islet-reactive CD8+ T-cell repertoire that is 
predominantly naïve and largely overlapping between T1D and healthy subjects (Culina et al., 
2018). These findings reveal a general leakiness of central tolerance irrespective of T1D 
status, begging the question of what determines T1D progression versus the maintenance of a 
‘benign’ state of autoimmunity. One hypothesis is that the target β cell and its response to 
inflammation may be critical in the progression toward T1D in the face of similar 
autoimmune T-cell repertoires across individuals. 
In this context, it is crucial to understand the ‘image’ that human β cells deliver to CD8+ T 
cells through pHLA-I complexes. To this end, we implemented a strategy combining HLA-I 
peptidomics on β cells and RNAseq analysis of the splice isoforms transcribed by primary 
islets exposed or not to inflammatory cytokines and by thymic medullary epithelial cells 




The HLA-I peptidome of human β cells is enriched by cytokine exposure and displays 
the expected amino-acid length and motifs.  
Our first epitope discovery pipeline employed HLA-I peptidomics experiments on the ECN90 
β-cell line (Culina et al., 2018), which carries the HLA-I haplotype 
A*02:01/A*03:01/B*40:01/B*49:01/C*03:04/C*07:01 (A2/A3/B40/B49/C3/C7 from here 
on). ECN90 β cells were cultured overnight with or without interferon (IFN)-γ, alone or in 
combination with tumor necrosis factor (TNF)-α and interleukin (IL)-1β, and lysed to 
immunopurify pHLA-I complexes. HLA-I-bound peptides were then analyzed by liquid 
chromatography-tandem mass spectrometry (LC-MS/MS). Although ECN90 β cells 
expressed surface HLA-I under basal conditions, this expression was significantly upregulated 
upon cytokine treatment (Fig. 1A-B), without significant cell death (Culina et al., 2018). The 
2,997 eluted peptides were mostly (93%) 8-12-mers (Fig. 1C), i.e. the length required for 
HLA-I binding. The amino acid (aa) identity at pHLA-I anchor positions (p2 and p9) also 
revealed the preferences expected based on the aforementioned HLA-I haplotype (Fig. 1D-E). 
In line with the observed HLA-I upregulation, the number of eluted peptides was significantly 
higher in the presence of cytokines, and higher in β cells exposed to IFN-γ, TNF-α and IL-1β 
compared with IFN-γ alone (Fig. 1F).  
These peptide datasets were subsequently analyzed using a stepwise bioinformatics pipeline 
(Fig. 1G). First, only peptides that were reproducibly detected in at least 2 of 5 biological 
replicates (85%; all percentages are given in relation to the number of peptides retained by the 
previous filter) and that displayed the expected 8-12-aa length (93%) were selected. β-cell-
enriched peptides (both conventional and with PTMs, excluding those derived from peptide or 
mRNA splicing; red pipeline in Fig. 1G) were subsequently filtered based on non-ubiquitous 
(16%) and enriched β-cell expression (34%) of their source proteins. For other non-
 6 
conventional peptides (i.e. PTM or transcriptional variants), no expression filter was applied, 
as these species could be β-cell-specific in spite of a ubiquitous expression of the source 
protein or mRNA. PTM peptides (methionine, tryptophan, histidine and cysteine oxidation 
tryptophan conversion to kynurenine) derived from ubiquitous proteins accounted for 8% of 
the whole dataset (blue pipeline in Fig. 1G). Compounds potentially corresponding to peptide 
splice variants (0.5%; brown pipeline) were identified using an in-house script (Fig. S1 and 
Data S1) based on reported peptide splicing preferences (Berkers et al., 2015) applied to 
known and putative Ags.    
For peptides derived from mRNA splice variants (dotted and green pipeline in Fig. 1G), the 
peptidomics dataset was interrogated against RNAseq datasets from primary human islets 
exposed or not to cytokines and from human mTECs (Data S2). First, higher gene expression 
can favor peptide processing and presentation. Hence, mRNA splice variants were selected 
based on a median Reads Per Kilobase per Million mapped reads (RPKM)>5 in islets (27%), 
based on the median RPKM of known islet Ags (Eizirik et al., 2012). Second, mRNA 
isoforms poorly expressed in mTECs might favor T-cell escape from clonal deletion. Thus, 
mRNA variants with a RPKM<0.1 in mTECs or with a fold-decrease>100 vs. islets were 
selected (6%). Third, we selected mRNA isoforms with >10-fold higher expression in islets 
vs. other tissues. We then analyzed the predicted aa neo-sequences encoded by these mRNA 
variants, yielding 88/166 mRNA variants (53%) and 336 peptide neo-sequences that were 
used to interrogate the HLA-I peptidomics dataset, with 2 hits found. Finally, each dataset 
was filtered to retain only those peptides found enriched in HLA-I- vs. mock-purified 
samples, leading to the overall exclusion of 48% hits. We focused on predicted HLA-A2-
restricted peptides for subsequent HLA-A2 binding and CD8+ T-cell recognition studies.  
Collectively, these results show that inflammatory cytokines increase pHLA-I presentation 
and that these peptides display the aa signatures required for HLA-I binding. 
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pHLA-I complexes from human β cells are enriched in peptides derived from secretory 
granule proteins, including known PPI epitopes.  
The filtered HLA-I peptidomics dataset obtained is described in Fig. 2 and detailed in Table 
S1. While 42/98 (43%) eluted peptides were shared among basal and cytokine-treated 
conditions, 45/98 (46%) peptides were only detected upon cytokine exposure (Fig. 2A). Also 
quantitatively, most peptides (62/98; 63%) were exclusively or more presented in cytokine-
treated ECN90 β cells (Table S1). 
Among the 40 source proteins of HLA-I-eluted peptides (Fig. 2B), the most represented ones 
were the known islet Ags CHGA (n=15 peptides) and PPI (n=12, plus one derived from an 
INS-006 mRNA splice variants). Besides the other known Ag IA-2 (PTPRN; n=3), the 5 top 
scoring proteins included two putative Ags: Kinesin Family Member 1A (KIF1A; n=9) and 
Secretogranin V (SCG5/7B2; n=3, plus one derived from a SCG5-009 mRNA splice variant). 
Other proteins included known Ags, i.e. GAD2 (GAD65), SLC30A8 (ZnT8) and IAPP (splice 
peptide), and several putative ones. Notably, all the HLA-A2-restricted PPI peptides 
identified, namely PPI2-10, PPI6-14, PPI15-24, PPI29-38 (INSB5-14) and PPI34-42 (INSB10-18) (Fig. 
2C), are already described as major CD8+ T-cell epitopes, thus validating our discovery 
strategy. Source proteins were enriched for insulin granule products (14/42, 33%; Fig. 2D), 
namely CHGA, INS, SCG5, PTPRN, ATP-binding cassette sub-family C member 8 
(ABCC8), proprotein convertase 1 (PCSK1/PC1), urocortin-3 (UCN3), chromogranin B 
(CHGB), carboxypeptidase E (CPE), proprotein convertase 2 (PCSK2/PC2), secretogranin III 
(SCG3), SLC30A8; and IAPP and neuropeptide Y (NPY) generating splice peptides. The 
predicted HLA-I restrictions of these peptides (Fig. 2E) comprised all the alleles expressed by 
ECN90 β cells, while 10% of restrictions could not be assigned. For peptides derived from β-
cell-enriched proteins, 11/98 (11%) carried PTMs, with most of them (8/11; 73%) 
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representing variants of unmodified peptides identified in this same dataset. Most of these 
modifications (7/11; 64%) were M(+15.99) methionine, C(+47.98) cysteine and W(+15.99) 
tryptophan oxidations, with W(+3.99) tryptophan to kynurenine transitions also detected. The 
99 PTM peptides derived from ubiquitous source proteins are listed in Table S2.    
To validate the results obtained using the ECN90 β-cell line, a HLA-A2+ primary human islet 
preparation that did not share other HLA-I alleles with ECN90 cells was analyzed similarly. 
The major source proteins of the HLA-I-bound peptides identified were largely overlapping 
with those found in ECN90 cells (Fig. 2F), with INS (n=12 peptides), CHGA (n=4), KIF1A 
(n=3) and SCG5 (n=3) ranking highest for both cells, and CHGB (n=3), PCSK2 (n=1) and an 
identical IAPP splice peptide also detected in both. When analyzing the identity of individual 
peptides (including length and PTM variants) (Table S3), 16/33 (48%) were shared between 
ECN90 and primary islet cells. This common repertoire increased to 12/13 peptides (92%) 
when considering only predicted HLA-A2 binders, supporting the validity of the ECN90 β-
cell model. Of note, shared peptides included all the PPI species already described as CD8+ T-
cell epitopes, SCG5186-196 along with a shorter SCG5186-195 variant with higher HLA-A2 
affinity, and the IAPP15-17/IAPP5-10 splice peptide VAL/KLQVFL. Although this product 
could also reflect PTPRN596-598/IAPP5-10 trans-splicing, IAPP15-17/IAPP5-10 is more likely 
because the intra-protein vicinity of these fragments is more favorable for transpeptidation. 
The new hits identified were mostly predicted to bind to the HLA-I molecules not shared with 
ECN90 cells, barring an HLA-A2-restricted CHGB440-448 peptide retained for further 
validation. Contrary to ECN90 cells, most peptides were detected at similar levels under basal 
and cytokine-treated conditions (Table S3). This mirrored a higher basal HLA-I expression in 
primary islets, possibly reflecting peri-mortem and tissue isolation stress conditions, which 
was less upregulated by cytokine treatment (Fig. 1G). Moreover, detection sensitivity may 
have been limited by the concomitant isolation of non-β-cell peptides, i.e. pancreatic 
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polypeptide- and glucagon-derived sequences likely eluted from δ and α cells (n=4 and 5, 
respectively; not shown because excluded by the β-cell enrichment filter). 
The fragmentation profile of the identified peptides was confirmed by comparing their 
MS/MS spectra with those of the corresponding synthetic peptides. Finally, the predicted 
HLA-A2 binding was experimentally verified (Fig. S2A-H), leading to the final selection of 
18/19 (95%) HLA-I-eluted peptides for CD8+ T-cell studies (including CHGB440-448 eluted 
from primary islets).    
Collectively, these data show that β cells process and present several known HLA-A2-
restricted PPI epitopes and additional candidate ones, which are enriched for secretory granule 
products.  
 
In silico analysis of mRNA splice variants yields additional predicted neo-Ag peptides. 
The RNAseq dataset used for assigning m/z species was further mined in silico, independently 
of the HLA-I peptidomics pipeline, to identify other potential HLA-A2-restricted peptides 
(Fig. 1G, dotted pipeline). Selection was based on a predicted HLA-A2 binding, a 9-10-aa 
length and a neo-sequence stretch ≥3 aa, with 39 candidates retained (Fig. S2I). These were 
splice variants of known β-cell Ags (GAD2-003, IAPP-002, IAPP-004, PTPRN-021, 
SLC30A8-002) and of candidate ones. Most of the source mRNA splice variants (35/39, 90%) 
were similarly expressed in untreated and cytokine-treated islets. HLA-A2 binding was 
experimentally confirmed for 34/39 candidates (87%; Fig. S2I), which were retained for 
further validation along with the 18 HLA-A2 binders identified by HLA-I peptidomics.   
 
HLA-A2-restricted β-cell peptides are targeted by a circulating naïve CD8+ T-cell 
repertoire in healthy donors. 
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We previously documented that the vast majority of individuals, both type 1 diabetic and 
healthy, harbor similar frequencies of circulating, predominantly naïve HLA-A2-restricted 
CD8+ T cells reactive to known PPI, GAD65, IA-2, IGRP and ZnT8 epitopes (Culina et al., 
2018). Similarly, we reasoned that the presence of a cognate naïve CD8+ T-cell repertoire is 
the preliminary requirement for the immunogenicity of the HLA-A2-restricted candidate 
epitopes identified in the in vitro HLA-I peptidomics and in silico transcriptomics pipeline 
(n=52; 18 and 34, respectively). We therefore started by screening these candidates for 
recognition by circulating CD8+ T cells in HLA-A2+ healthy donors (Table S4), using 
combinatorial double-coded HLA-A2 multimers (MMrs) loaded with the corresponding 
synthetic peptides (Culina et al., 2018). We retained those candidates that harbored a cognate 
naïve CD8+ T-cell repertoire, based on i) the frequency of this repertoire, which is typically in 
the range of 1-50/106 CD8+ T cells (Alanio et al., 2010; Culina et al., 2018); and ii) the pattern 
of HLA-A2 MMr staining, which is usually clustered rather than spread in the presence of a 
specific epitope-reactive population (James et al., 2018). The gating strategy is presented in 
Fig. 3 and representative dot plots in Fig. 4A-F. Using these two criteria, several candidate 
epitopes displayed a cognate naïve CD8+ T-cell repertoire in the expected range in a sizable 
fraction (≥50%) of the healthy individuals analyzed. The frequency of CD8+ T cells 
recognizing the known β-cell epitope PPI6-14 previously analyzed (Culina et al., 2018) also 
fell in the same range, with some outliers noted. In total, 9/18 HLA-I-eluted peptides (50%; 
Fig. 4G) were validated, namely CHGA344-352, insulin gene enhancer protein ISL1276-284, 
potassium channel subfamily K member 16 (KCNK16)129-137, KIF1A1347-1355, PCSK230-38, 
SCG5186-195, SCG5-009186-194 and UCN31-9. Despite recognition in only 1 of 6 donors 
analyzed, the peptide splice product IAPP15-17/IAPP5-10 was also retained, since it was 
identified in both ECN90 and primary islet cells. Using the same criteria, 11/34 candidates 
selected in silico were validated (32%; Fig. 4H), namely cyclin I (CCNI)-00814-22, GAD2-
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003179-187, guanine nucleotide-binding protein G(s) subunit α isoforms short (GNAS)-03667-75, 
GNAS-036124-132, IAPP-00233-42, PTPRN-021392-402, PTPRN-021398-407, phogrin/receptor-type 
tyrosine-protein phosphatase N2 (PTPRN2)-00511-19, PTPRN2-00519-27, mitochondrial 
oligoribonuclease (REXO2)-0202-10, and SLC30A8-00216-25. As previously observed for other 
known β-cell epitopes (Culina et al., 2018), including the PPI6-14 here used as β-cell positive 
control, only a minority (median 16.4%, interquartile range 8.5-26.7%) of CD8+ T cells 
recognizing these candidate epitopes were Ag-experienced (CD45RA+CCR7‒, CD45RA‒
CCR7‒ or CD45RA‒CCR7+; Fig. 4I-J). Conversely, the Flu MP58-66 peptide included as viral 
positive control displayed the expected predominantly Ag-experienced phenotype. The 
complete list of the 20 candidates validated for CD8+ T-cell recognition is presented in Table 
1. All the peptides validated came from source proteins whose gene expression was detected 
in islets, both under basal and cytokine-treated conditions. One notable exception was SCG5-
009, whose expression was negligible under basal condition but strongly upregulated after 
cytokine treatment. Gene expression in mTECs was also negligible in all cases, with the 
exception of CHGA, ISL1 and SCG5. 
Collectively, these results show that most of the β-cell peptides identified display a cognate 
naïve CD8+ T-cell repertoire in the blood of healthy individuals, making them potential 
targets of islet autoimmunity.  
 
Circulating CD8+ T cells reactive to HLA-A2-restricted β-cell peptides display similar 
ex-vivo frequencies and a predominantly naïve phenotype in T1D and healthy subjects. 
Thirteen of the 20 β-cell peptides validated for recognition by a naïve CD8+ T-cell repertoire 
were selected for further ex-vivo combinatorial double-coded MMr validation using blood 
samples from HLA-A2+ recent-onset T1D and healthy subjects (n=10/each; Table S4). For 
naturally processed and presented peptides identified by HLA-I peptidomics, we focused on 6 
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insulin granule putative Ags, namely IAPP15-17/5-10, PCSK230-38, SCG5186-195, SCG5-009186-194 
and UCN31-9; and the transcription factor ISL1276-284. A less focused selection was made for 7 
predicted mRNA splice peptides, as these may be derived from short-lived, unstable defective 
ribosomal products (DRiPs) (Anton and Yewdell, 2014). CCNI-00814-22, GAD2-003179-187, 
GNAS-03667-75, GNAS-036124-132, IAPP-00233-42, PTPRN2-00511-19 and SLC30A8-00216-25 
were thus selected. The frequency of circulating CD8+ T cells recognizing these peptides and 
the control PPI6-14 epitope was similar in T1D and healthy subjects (Fig. 5A), and fell in the 
same range (1-50/106 CD8+ T cells) detected in the preliminary screening performed on 
healthy subjects using different fluorochrome-labeled MMr combinations (Fig. 4G-H), with 
the exception of IAPP-00233-42 for which virtually no MMr
+ cells were detected. As in the 
screening round, frequencies were particularly high and clustered for 4 CD8+ T-cell 
specificities, namely SCG5-009186-194, UCN31-9, CCNI-00814-22 and GAD2-003179-187. As 
reported for PPI6-14 and other known β-cell epitopes (Culina et al., 2018), these MMr
+ cells 
were predominantly naïve in both T1D and healthy subjects (Fig. 5B; median 8.3%, 
interquartile range 0-20.0%).        
Collectively, these results show that the β-cell peptides identified are targeted by similar 
frequencies of predominantly naïve circulating CD8+ T cells in T1D and healthy subjects. 
 
Pancreas-infiltrating cells reactive tothe HLA-A2-restricted IAPP15-17/5-10, ISL1276-284 and 
UCN31-9 peptides are enriched in T1D patients. 
Given the lack of difference in frequency or markers of prior Ag encounter observed for 
circulating islet-reactive CD8+ T cells between T1D and healthy donors, we verified whether 
these reactivities were present in the pancreas-infiltrating cells of HLA-A2+ T1D, aAb+, non-
diabetic and type 2 diabetes donors by in-situ MMr staining of consecutive tissue sections 
from the Network for Pancreatic Organ Donors (nPOD) repository. We selected IAPP15-17/5-10, 
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ISL1276-284 and UCN31-9, which are representative of the frequency range detected in 
peripheral blood and stained positive in a preliminary screening on pancreatic sections from 
one T1D donor (Fig. S3; with SCG-009186-194 also staining positive).Fig. 6A-R displays 
representative images, with scattered MMr+ cells in the vicinity of the islet or exocrine tissue. 
The β-cell ZnT8186–194 peptide and the melanocyte MelanA26-35 peptide provided positive and 
negative controls, respectively (Culina et al., 2018). Results are summarized in Fig. 6S and 
Table S5. Whereas IAPP15-17/5-10, ISL1276-284, UCN31-9 (and ZnT8186–194) MMr
+ cells were 
significantly more abundant than MelanA26–35 MMr
+ cells in T1D, aAb+ (barring UCN31-9), 
and non-diabetic cases (barring IAPP15-17/5-10 and UCN31-9), all islet MMr
+ cells were 
enriched in the pancreata of T1D vs. non-diabetic cases, and also in the pancreata of aAb+ vs. 
non-diabetic cases for IAPP15-17/5-10 and ISL1276-284. In contrast, islet and MelanA26-35 MMr
+ 
cells were present at similar densities across all groups in pancreatic lymph node (PLN) 
sections from the same donors (Fig. 6T), as reported for ZnT8186–194 (Culina et al., 2018). 
Fluorescent confocal microscopy on pancreas sections from one T1D donor (Fig. 6U-W) 
detected 60 CD8+ cells (2.3 cells/mm2), among which 37 (61.7%) were CD45RO+ and 2 
CD45RO+MMr+ using pooled IAPP15-17/5-10/ISL1276-284/UCN31-9 MMrs (5.4% of 
CD8+CD45RO+ and 3.3% of total CD8+ cells), suggesting that pancreas-infiltrating islet 
MMr+ cells are Ag-experienced CD8+ T cells. 
Collectively, these results show that IAPP15-17/5-10-, ISL1276-284- and UCN31-9-reactive cells are 
enriched in the pancreas of T1D patients, similarly to ZnT8186-194-reactive cells (Culina et al., 
2018), lending support to their relevance in T1D.   
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DISCUSSION 
We here provide a first catalogue of the HLA-I peptidome of human β cells, using an 
immortalized β-cell line naturally expressing the most prevalent HLA-A2 variant. This 
cellular model proved informative, since several HLA-A2-restricted peptides identified were 
also naturally processed and presented by primary human islets. The technical strengths of our 
approach are the combined HLA-I peptidomics and transcriptomics pipelines; the use of small 
cell numbers (20x106) for HLA-I purification, despite its low expression in β cells compared 
with professional Ag-presenting cells; and the use of a mock immunopurification to exclude 
peptides not bound to HLA-I. One limitation is the lower sensitivity of the LC-MS/MS data-
dependent acquisition discovery mode used compared with targeted strategies. Indeed, 
previous studies on mouse NIT-1 β cells (Dudek et al., 2012) detected low amounts of the 
immunodominant IGRP206-214 peptide only after using a targeted approach on IFN-γ-treated 
cells. Nonetheless, our sensitivity proved sufficient to detect several known β-cell Ags. 
Although this did not allow a precise quantitation of pHLA-I complexes, it allowed to detect 
HLA-I-bound peptides without a priori hypotheses. 
Expectedly, only ~5% of the HLA-I peptidome originated from proteins preferentially 
expressed in β cells. Multiple PPI peptides described as major CD8+ T-cell epitopes were 
detected, validating our discovery approach and documenting their natural processing and 
presentation by β cells. Peptides derived from all the other known β-cell Ags were also 
identified, namely CHGA, PTPRN, GAD2, SLC30A8 and IAPP. The only known Ag missing 
was IGRP, which may reflect low amounts of IGRP pHLA-I complexes, as reported for 
murine NIT-1 β cells (Dudek et al., 2012). The same may be true for the ZnT8186-194 epitope, 
for which a concordant m/z value was identified at the MS1 level in several HLA-I-purified 
ECN90 samples (1/5, 5/5 and 4/5 for basal, IFN-γ-treated and IFN-γ/TNF-α/IL-1β-treated 
conditions, respectively; 1/15 mock-purified samples). More importantly, several as yet 
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undescribed peptides were identified, many of which were derived from secretory granule 
proteins, namely CHGA, INS, SCG5, PTPRN, ABCC8, PCSK1, UCN3, CHGB, CPE, 
PCSK2, SCG3, SCL30A8, NPY and IAPP. This is not surprising considering that granule 
proteins are abundantly synthesized by β cells, thus favoring HLA-I presentation (Bassani-
Sternberg et al., 2015). Their fast turnover also increases the odds of producing misfolded 
proteins, which are rapidly routed toward proteasomal degradation and HLA-I presentation 
(Anton and Yewdell, 2014). 
mRNA alternative splicing is another mechanism frequently leading to unstable DRiPs, which 
are rapidly degraded through different pathways (Anton and Yewdell, 2014). Moreover, these 
mRNA isoforms may translate aa neo-sequences when exons are either added or skipped 
compared to the canonical mRNA. We therefore performed a parallel in silico prediction of 
mRNA-translated peptide neo-sequences. Although no proof of natural processing and 
presentation could be provided for most of these theoretical peptide products, the finding of a 
naïve CD8+ T-cell repertoire capable of recognizing them supports their potential relevance as 
autoimmune T-cell targets. Of note, peptides derived from the alternative open reading frame 
INS mRNA (Kracht et al., 2017) were not detected.   
Despite presentation by HLA-I molecules, peptides may still be ignored by CD8+ T cells, thus 
not triggering an autoimmune response. This primarily reflects the absence of a cognate naïve 
repertoire available for priming (Alanio et al., 2010). We therefore first screened healthy 
individuals for the presence of cognate naïve CD8+ T cells, which were found for several 
peptides. Although the poor expression of the genes encoding these proteins in mTECs may 
exert a facilitating effect, this is not an absolute requirement for peripheral CD8+ T-cell 
recognition. Indeed, CHGA, ISL1 and SCG5 were expressed in mTECs, and yet targeted by 
CD8+ T cells at frequencies comparable to those of T cells recognizing Ags not expressed in 
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mTECs, in line with the increasing appreciation that thymic clonal deletion is highly 
incomplete (Culina et al., 2018). 
Based on our previous findings on known β-cell epitopes (Culina et al., 2018), we did not 
expect differences in circulating CD8+ T cells between T1D and healthy subjects, because the 
Ag-experienced fraction is rather limited, likely reflecting sequestration in the target tissue. 
This was also the case for the candidates studied herein, and for the well-described control 
PPI6-14 epitope eluted from pHLA-I complexes. Together with the reactivity against IAPP15-
17/5-10, ISL1276-284 and UCN3 1-9, which was preferentially detected in the pancreatic infiltrates 
of T1D (and aAb+) donors and localized in CD8+CD45RO+ T cells in one T1D case, these 
findings provide a first validation of their disease relevance. The degree of evidence for a 
relevance to T1D is higher for those peptides targeted by CD8+ T cells and naturally 
processed and presented by β cells, i.e. SCG5186-195, PCSK230-38, UCN31-9 and ISL1276-284. 
These also include the neo-antigenic peptides SCG-009186-194 and IAPP15-17/5-10 generated by 
mRNA splicing and transpeptidation, respectively.  
Complementary analyses of the current HLA-I peptidomics dataset will yield additional 
information. First, only few PTMs were searched and a dedicated analysis is required. This 
should include the distinction between biological and experimentally induced PTMs, since 
some of them, e.g. the tryptophan to kynurenine conversion of the PPI15-24 peptide, were 
similarly detected in the corresponding synthetic peptides. Second, an unbiased analysis of 
transpeptidation beyond the described aa preference rules (Berkers et al., 2015) will likely 
yield additional fusion peptides, which may account for up to one third of the HLA-I 
peptidome (Liepe et al., 2016). Third, only HLA-A2-restricted peptides were analyzed for T-
cell recognition, leaving several HLA-A3- and HLA-B39-restricted candidates available for 
follow-up studies. HLA-B39 was expressed by the primary islets analyzed and, although rare, 
is the HLA-I variant most strongly associated with T1D (Nejentsev et al., 2007).   
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Finally, the HLA-I peptidome obtained allows to formulate hypotheses about the Ag-
processing pathways employed by β cells. Some peptides (UCN31-9, IAPP15-17/5-10, PPI2-10, 
PPI6-14, PPI15-24) are located in the leader sequence of proteins abundantly produced by β cells, 
which is cleaved in the ER at each protein synthesis. These byproducts may therefore provide 
a rich peptide source for HLA-I presentation and likely follow alternative Ag-processing 
pathways within the ER, independent of proteasome cleavage (El Hage et al., 2008; Skowera 
et al., 2008). It is also noteworthy that several source proteins of HLA-I-bound peptides, i.e. 
CHGA, INS, SCG5, PCSK1, UCN3, CHGB, CPE, PCSK2, SCG3, NPY and IAPP are 
synthesized as precursors and incorporated into β-cell granules, where they undergo 
intermediate processing by proconvertases to yield bioactive products. A notable example is 
SCG5, a PCSK2 chaperone that is gradually degraded along the secretory pathway to 
competitively prevent the premature activation of PCSK2 by autocatalytic cleavage (Mbikay 
et al., 2001). This continuous degradation may explain the abundance of HLA-I-bound SCG5 
peptides. In this respect, the C-terminal SCG5186-195 peptide is located between furin 
(RRKRR) and PCSK2 (KK) cleavage sites and, similar to leader sequence peptides, may 
behave as a byproduct of the intermediate SCG5 processing (Bartolomucci et al., 2011). The 
same is true for several CHGA peptides, e.g. CHGA344-352, which maps to the WE-14 
neuropeptide produced by CHGA cleavage at dibasic KR motifs (Bartolomucci et al., 2011).  
These peptides may access the HLA-I pathway following crinophagy, i.e. the disposal of 
unused secretory granules through fusion with lysosomes (Goginashvili et al., 2015; 
Weckman et al., 2014). In this scenario, islet inflammation may provide a key switch for 
progression of the ‘benign’ autoimmunity of healthy individuals toward T1D at two levels: on 
T cells, by impairing peripheral immunoregulation; and on β cells, by increasing the overall 
number of pHLA-I complexes available for T-cell recognition. 
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LIMITATIONS OF THIS STUDY 
One limitation of our work is that the pathogenic role of the CD8+ T cells recognizing the 
epitopes described herein remains to be definitely established. Islets from T1D patients were 
not available for HLA peptidomics studies, and the enrichment of these T cells in the pancreas 
of patients could reflect a cause or consequence of disease. It should be noted however that 
the same uncertainty applies to all the other islet-reactive T-cell specificities described to date. 
The capacity to kill β cells that has been described for some of them cannot be taken as 
conclusive evidence for their pathogenic role, since T-cell clones obtained from T1D and 
healthy donors kill β cells to a similar extent (Culina et al., 2018). Nonetheless, we here 
provide two key findings. First, that these epitopes are naturally processed and presented by β 
cells and are covered by the natural CD8+ T-cell repertoire, hence providing potential targets 
for β-cell killing. Second, that the CD8+ T cells recognizing them accumulate preferentially in 
the pancreas of T1D patients. This latter finding is unlikely to be serendipitous, as it did not 
apply to CD8+ T cells recognizing the melanocyte MelanA26-35 epitope, despite the fact that 
their frequency in the blood is ~100-fold higher than for islet epitope-reactive CD8+ T cells 
(Culina et al., 2018).            
In conclusion, the HLA-I peptidome of human β cells described herein provides information 
about the Ag processing features of β cells, the targets amenable to autoimmune recognition 
and a valuable tool for developing T-cell biomarkers and tolerogenic vaccines.   
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Figure 1. The HLA-I peptidome of human β cells is enriched by cytokine exposure and 
displays the expected amino-acid length and motifs. (A) HLA-I expression detected by 
flow cytometry on ECN90 β cells under basal (red), IFN-γ-stimulated (blue) and IFN-γ/TNF-
α/IL-1β-stimulated conditions (green). The grey profile displays IFN-γ/TNF-α/IL-1β-
stimulated cells stained with an isotype control monoclonal antibody (mAb; the identical 
profiles of basal and IFN-γ-stimulated conditions are not shown). (B) HLA-I heavy chain 
expression detected by Western blot on the same cell aliquots, with α-tubulin bands shown as 
loading control. (C) aa length of the 2,997 peptides detected in ≥2 out of 5 biological 
replicates. (D) Sequence logo plots displaying the HLA-A2 (top), -A3 (middle) and -B40/B49 
(bottom) binding motifs for the 3 major Gibbs clusters. The X-axis shows the residue position 
within nonamer peptide sequences. The Y-axis shows the information content, with the size of 
each aa symbol proportional to its frequency. (E) Heat map of the predicted HLA-I binding 
affinities of nonamer peptides. Each column represents a unique peptide. Red, green and grey 
shades indicate high binders (KD≤50 nM), low binders (KD≤2,000 nM) and non-binders 
(KD>2,000 nM), respectively. (F) Number of peptides identified in ECN90 β cells. **p=0.008 
and *p=0.02 by Mann-Whitney test. (G) The bioinformatics analysis pipeline used (see STAR 
methods for details). The 3,544 peptides identified were first filtered based on inter-sample 
reproducibility (n=2,997) and aa length (n=2,795). From this dataset, we identified 217 
peptides derived from ubiquitous proteins carrying PTMs (blue), from which 99 (Table S2) 
were enriched in HLA-I-purified samples; and 15 peptide splice variants (brown; see Fig. S1 
for the identification strategy), from which 10 were enriched in HLA-I-purified samples. The 
remaining β-cell-enriched peptides (both conventional and with PTMs; red) were filtered 
based on non-ubiquitous expression (n=411), β-cell-enriched expression (n=139) and 
enrichment in HLA-I-purified samples (n=86; Table S1). Finally, mRNA splice variants 
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(green, n=2) were identified by searching the HLA-I peptidomics dataset against the predicted 
aa neo-sequences obtained from RNAseq analysis. For this RNAseq pipeline (dashed boxes), 
53,280 mRNAs were filtered based on islet mRNA expression (n=14,504), low mTEC mRNA 
expression (n=908), islet enrichment compared to control tissues (n=166) and generation of a 
predicted aa neo-sequence (n=88). The 336 predicted aa neo-sequences obtained from these 
88 mRNA variants were analyzed in parallel for the presence of predicted HLA-2 binders 
(n=66) with a 9-10-aa length (n=43) and a neo-sequence of ≥3 aa (n=39). The indicated 
epitope candidates were further filtered on predicted and experimental HLA-A2 binding to 
focus subsequent CD8+ T-cell recognition studies on HLA-A2-restricted peptides (see text).    
 
Figure 2. pHLA-I complexes of human β cells are enriched in peptides derived from 
secretory granule proteins, including known PPI epitopes. (A) Number of peptides (n=86 
from β-cell-enriched proteins, n=10 transpeptidation products, n=2 mRNA splice products) 
identified in ECN90 β cells after bioinformatics filtering (Fig. 1G). (B) Source proteins of the 
98 peptides (detailed in Table S1). (C) Mapping of HLA-A2-restricted PPI peptides identified 
in ECN90 β cells. PTM variants (see Table S1) and a PPI15-26 length variant (in italics) were 
also identified. (D) Origin of the 42 proteins yielding the 98 peptides identified in ECN90 β 
cells, including splice peptides generated from IAPP and NPY. (E) Predicted HLA-I 
restrictions of the same peptides. (F) Source proteins of the 33 peptides (Table S3) identified 
in HLA-A2+ primary human islets. Asterisks indicate proteins for which some peptides 
identified were identical or length variants compared to those identified in ECN90 β cells, 
including the identical IAPP15-17/5-10 splice peptide. Exploded slices indicate source proteins 
not identified in ECN90 β cells. (G) HLA-I heavy chain expression detected by Western blot 
on primary islets and ECN90 β cells under basal and IFN-γ/TNF-α/IL-1β-stimulated 
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conditions, with β-actin bands shown as loading control. A representative islet preparation out 
of 3 analyzed is shown. 
 
Figure 3. Gating strategy for the combinatorial analysis of β-cell peptide MMr+CD8+ T 
cells in T1D and healthy subjects. (A) Frozen-thawed peripheral blood mononuclear cells 
(PBMCs) from T1D donor D314D were magnetically depleted of CD8– cells before staining, 
acquisition and analysis (see STAR Methods). Cells were sequentially gated on small 
lymphocytes, singlets, live cells (Live/Dead Aqua–), CD3+CD8+ T cells and total PE+, PE-
CF594+, APC+, BV650+, BV711+ and BV786+ MMr+ T cells. Using Boolean operators, these 
latter gates allowed to selectively visualize each double-MMr+ population by including only 
those events positive for the corresponding fluorochrome pair. (B-C) The final readout 
obtained for T1D donor D314D (B) and healthy donor H170S (C) is shown for the 15 
peptides analyzed. Events corresponding to each epitope-reactive population are overlaid in 
different colors within each plot, with MMr– events overlaid in light grey. The small dot plots 
on the right of each panel depict CD45RA (x-axis) and CCR7 (y-axis) expression in the 
corresponding MMr+ fraction. Numbers in each panel indicate the MMr+CD8+ T-cell 
frequency out of total CD8+ T cells and the percent naïve (CD45RA+CCR7+) fraction among 
MMr+ cells. 
 
Figure 4. HLA-A2-restricted β-cell peptides are targeted by a circulating naïve CD8+ T-
cell repertoire in healthy donors. MMr+CD8+ cells reactive to HLA-A2-binding β-cell 
peptides (Fig. S2) were stained ex vivo from PBMCs of 5-6 HLA-A2+ healthy donors (Table 
S4). (A-F) Representative dot plots of different MMr staining patterns: high frequency, 
clustered pattern (A; CCNI-00814-22); intermediate frequency, clustered pattern (B; SCG5186-
195); low frequency, clustered pattern (C; CHGB440-448); high frequency, spread pattern (D; 
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LARP4-006214-222); and the β-cell PPI6-14 (E) and viral Flu MP58-66 (F) positive controls. (G-
H) MMr+CD8+ cells reactive to β-cell peptides identified in HLA-I peptidomics (G) and 
RNAseq (H) pipelines. PPI6-14 and Flu MP58-66 peptides were included as controls. 
Frequencies out of total CD8+ T cells are depicted. Dotted lines indicate the expected 
frequency of naïve MMr+CD8+ T cells, bars show median values. The 20 β-cell peptides 
displaying the expected CD8+ T-cell frequency and a clustered MMr staining pattern were 
retained and are marked with an asterisk (2 asterisks for the 13 peptides further analyzed). β-
cell peptides in italics were excluded despite their cognate MMr+CD8+ T-cell frequencies 
because of their spread MMr staining pattern. At least 0.6x106 CD8+ T cells were counted for 
each donor (median 1.4x106, range 0.6-4.9x106). (I-J) Percent Ag-experienced cells 
(CD45RA-CCR7-, CD45RA+CCR7- and CD45RA-CCR7+) out of total MMr+ cells for the β-
cell peptides depicted in panels G-H, respectively. Data points with <5 MMr+ cells were 
excluded from this analysis (median 19 MMr+ cells, range 5-808 for β-cell peptides). NA, not 
available. 
 
Figure 5. Circulating CD8+ T cells reactive to HLA-A2-restricted β-cell peptides display 
similar ex-vivo frequencies and a predominantly naïve phenotype in T1D and healthy 
subjects. (A) Frequencies of MMr+CD8+ cells reactive to the indicated β-cell peptides in T1D 
(grey; n=10) and healthy subjects (white; n=10; donors listed in Table S4). PPI6-14 and Flu 
MP58-66 peptides were included as controls. At least 0.6x10
6 CD8+ T cells were counted for 
each donor (median 1.0x106, range 0.6-2.4x106). (B) Percent Ag-experienced cells out of total 
MMr+ cells for the β-cell peptides depicted in panel A. Data points with <5 MMr+ cells were 
excluded (median 14 MMr+ cells, range 5-160 for β-cell peptides). Bars show median values. 
NA, not available. 
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Fig. 6. Pancreas-infiltrating cells reactive to the HLA-A2-restricted IAPP15-17/5-10, 
ISL1276-284 and UCN31-9 peptides are enriched in T1D patients. Pancreas sections from 
nPOD cases (Table S5) were immunohistochemically stained in situ with MMrs loaded with 
IAPP15-17/5-10, ISL1276-284, UCN31-9 (selected from Fig. S3), positive control ZnT8186-194 and 
negative control melanocyte MelanA26-35 peptide. (A-D, I-L, Q-R) Representative pancreas 
images (20X magnification; scale bar 100 μm). (E-H, M-P) Higher magnification of the 
dotted areas highlighted on the left of each panel (scale bar 40 μm for panels E, M; 38 µm for 
F, N; 45 µm for G, O; 36 µm for H, P). (S-T) Number of MMr+ cells/mm2 section area of 
pancreas (S) and PLNs (T). Each point represents an individual case, bars indicate median 
values. *P ≤ 0.05 and **P ≤ 0.009 by Mann-Whitney test. NA, not assessed. (U-W) 
Fluorescent confocal microscopy on pancreas sections from T1D EUnPOD case #060217 for 
CD8 (green), CD45RO (blue) and pooled IAPP15-17/5-10/ISL1276-284/UCN31-9 MMrs (red). 
Examples of CD8+CD45RO‒MMr‒, CD8+CD45RO+MMr‒ and CD8+CD45RO+MMr+ cells 





Table 1. Summary of β-cell peptides tested for recognition by circulating naïve CD8+ T cells of healthy subjects. The peptides presented in 
Fig. 4 are alphabetically listed and classified according to type (conventional, peptide splice and mRNA splice). The corresponding median 
RPKM values detected in islets (control- and cytokine-treated) and mTECs (HLA Class IIhi and Class IIlo) are shown. For proteins not arising 
from alternative mRNA splicing, RPKM values refer to the most prevalent islet mRNA isoform coding for the corresponding peptide. 
Subsequent columns detail the number of T-cell+ donors (≥5/107 MMr+ cells counted), the median MMr+ frequency, the median percent Ag-
experienced cells within the MMr+ fraction (for peptides/donors with ≥5 MMr+ cells), the number of donors with ≥5 MMr+ cells, the MMr 
staining pattern (clustered, spread or not detected, ND) and the final validation outcome. The 20 validated β-cell peptides (in bold) displayed the 
expected CD8+ T-cell frequency and a clustered MMr staining pattern and are marked with an asterisk (2 asterisks for the 13 peptides further 
analyzed). NA, not available. 
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ACLY-004 70-78 GLVGVNLTL mRNA splice 22.5 5.7 0.0 0.0 0/6 0.00E+00 NA 0/6 ND No 
C15orf48-003 73-81 FLLQNPCPL mRNA splice 9.8 18.1 0.0 0.0 0/6 8.30E-08 29 1/6 Spread No 
C16orf70-010 44-53 VLYSEQVIEV mRNA splice 0.7 12.3 0.0 0.0 0/6 2.54E-07 14 1/6 Spread No 
CCNI-008 11-19 ILDKLNWDL mRNA splice 41.0 25.9 0.4 0.3 1/6 1.05E-07 20 1/6 Spread No 
**CCNI-008 14-22 KLNWDLHTA  mRNA splice 41.0 25.9 0.4 0.3 4/6 5.05E-06 10 6/6 Clustered Yes 
CCNI-008 53-61 SLPLNSVYV mRNA splice 41.0 25.9 0.4 0.3 1/6 5.20E-08 NA 0/6 Spread No 
*CHGA 344-352 KMDQLAKEL Conventional 587.2 1881.9 7.9 13.2 3/6 9.75E-07 18 5/6 Clustered Yes 
CHGA 402-411 SLEAGLPLQV Conventional 587.2 1881.9 7.9 13.2 0/6 1.66E-07 NA 0/6 Spread No 
CHGB 440-448 FLGEGHHRV Conventional 1212.4 935.2 9.6 18.4 1/6 6.67E-07 28 4/6 Clustered No 
CLDN7-008 60-68 GMMSCKIGL mRNA splice 20.8 17.5 0.0 0.1 0/6 0.00E+00 NA 0/6 ND No 
FAM171B 19-28 VLLKARLVPA Conventional 4.3 4.0 6.5 5.0 3/6 1.70E-06 7 5/6 Spread No 
**GAD2-003 179-187 KIIKLFFRL mRNA splice 22.2 21.2 0.0 0.0 5/6 5.14E-06 19 6/6 Clustered Yes 
GNAS-002 31-39 ALLWLSCSI mRNA splice 256.1 123.2 0.6 0.0 0/6 4.92E-07 30 2/6 Clustered No 
GNAS-002 32-41 LLWLSCSIAL mRNA splice 256.1 123.2 0.6 0.0 0/6 0.00E+00 NA 0/6 ND No 
GNAS-002 34-42 WLSCSIALL mRNA splice 256.1 123.2 0.6 0.0 1/6 3.16E-07 23 2/6 Clustered No 
**GNAS-036 67-75 YMCTHRLLL mRNA splice 48.9 45.1 0.0 0.0 4/6 1.25E-06 9 5/6 Clustered Yes 
GNAS-036 67-76 YMCTHRLLLL mRNA splice 48.9 45.1 0.0 0.0 0/6 0.00E+00 NA 0/6 ND No 
**GNAS-036 124-132 AMSNLVPPV  mRNA splice 48.9 45.1 0.0 0.0 5/6 1.30E-06 14 5/6 Clustered Yes 
GNAS-036 185-194 QLIDCAQYFL mRNA splice 48.9 45.1 0.0 0.0 0/6 4.76E-08 NA 0/6 ND No 
GPR119 48-56 AVADTLIGV Conventional 9.4 7.4 0.0 0.0 0/6 1.26E-07 NA 0/6 Spread No 
**IAPP/IAPP 15-17/5-10 VALKLQVFL Peptide splice 1257.1 392.4 0.3 0.0 1/6 2.45E-07 9 1/6 Clustered Yes 
**IAPP-002 33-42 VLSRNILLEL mRNA splice 74.0 24.3 0.0 0.0 3/6 9.63E-07 35 4/6 Clustered Yes 
IAPP-004 9-18 CLDQIPIFTV mRNA splice 609.8 257.1 0.0 0.0 1/6 2.59E-07 37 2/6 Clustered No 
IGF2BP3 552-560 KIQEILTQV Conventional 0.2 0.4 5.3 0.9 0/5 2.66E-07 24 4/5 Spread No 
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**ISL1 276-284 GLQANPVEV Conventional 26.2 27.9 17.0 26.9 3/6 1.83E-06 26 3/6 Clustered Yes 
*KCNK16 129-137 ALLGIPLNV Conventional 33.3 22.5 0.0 0.0 5/6 4.44E-06 13 6/6 Clustered Yes 
KCNK16-002 234-242 SLAAIWILL mRNA splice 33.3 22.5 0.0 0.0 0/6 4.37E-08 NA 0/6 ND No 
KCNK16-002 240-248 ILLGLAWLA mRNA splice 33.3 22.5 0.0 0.0 0/6 1.30E-07 NA 0/6 Spread No 
*KIF1A 1347-1355 VLDTSVAYV Conventional 19.5 17.7 1.0 1.9 3/6 2.25E-06 33 5/6 Clustered Yes 
KIF1A 1480-1488 KLSEMSVTL Conventional 19.5 17.7 1.0 1.9 0/5 5.2E-07 18.2 5/5 Spread No 
LARP4-006 214-222 RLMDSSIYS mRNA splice 6.8 10.5 0.0 0.0 2/6 8.95E-07 20 4/6 Spread No 
LARP4-006 355-363 YLQKETSTL mRNA splice 6.8 10.5 0.0 0.0 2/6 7.94E-07 21 5/6 Spread No 
LGMN-012 68-76 VMINPTPGI mRNA splice 0.0 10.9 0.0 0.0 0/6 0.00E+00 NA 0/6 ND No 
PCSK1-002 8-17 FLFFSQIGSL mRNA splice 16.2 13.8 0.0 0.0 0/6 0.00E+00 NA 0/6 ND No 
**PCSK2 30-38 FTNHFLVEL Conventional 73.2 43.4 0.7 0.0 4/6 1.25E-06 9 6/6 Clustered Yes 
PCSK2-001 11-19 AAAGFLFCV   mRNA splice 36.5 17.8 0.0 0.1 2/6 5.40E-07 23 2/6 Spread No 
PCSK2-001 15-23 FLFCVMVFA mRNA splice 36.5 17.8 0.0 0.1 2/6 3.79E-07 54 2/6 Spread No 
PDXDC1-013 174-183 YLCNQDVAFL mRNA splice 13.5 0.8 0.0 0.0 2/6 6.21E-07 17 3/6 Spread No 
PIK3R3 144-152 SLAQYNPKL Conventional 2.2 2.4 18.7 9.2 3/6 8.50E-07 12 4/6 Spread No 
PRPH 171-179 GLAEDLAAL Conventional 4.0 3.8 1.1 0.5 3/6 1.08E-06 19 5/6 Spread No 
*PTPRN-021 392-402 SLAAGVKLLEI mRNA splice 81.5 98.3 0.0 0.0 5/5 4.49E-06 17 5/5 Clustered Yes 
*PTPRN-021 398-407 KLLEILAEHV mRNA splice 81.5 98.3 0.0 0.0 5/5 4.30E-06 13 5/5 Clustered Yes 
PTPRN-021 402-409 ILAEHVHM mRNA splice 81.5 98.3 0.0 0.0 1/5 5.41E-07 9 4/5 Clustered No 
**PTPRN2-005 11-19 LLLLLPPRV mRNA splice 33.3 10.8 0.0 0.0 4/6 1.67E-06   3/6 Clustered Yes 
*PTPRN2-005 19-27 VLPAAPSSV  mRNA splice 33.3 10.8 0.0 0.0 6/6 5.53E-06 8 6/6 Clustered Yes 
*REXO2-020 2-10 SVANALWIV  mRNA splice 4.2 10.5 0.0 0.0 5/6 1.94E-06 28 5/6 Clustered Yes 
**SCG5 186-195 YLQGQRLDNV Conventional 252.5 163.2 3.2 2.9 5/6 1.16E-06 20 6/6 Clustered Yes 
**SCG5-009 186-194 FLSGAVNRL mRNA splice 0.3 41.4 0.0 0.0 5/5 6.62E-06 7 5/5 Clustered Yes 
**SLC30A8-002 16-25 KMYAFTLESV mRNA splice 43.1 38.1 0.3 0.0 4/6 1.33E-06 7 2/6 Clustered Yes 
ST18 304-312 SLLEQAIAL Conventional 8.2 4.8 0.2 0.5 3/6 6.70E-07 33 3/6 Spread No 
**UCN3 1-9 MLMPVHFLL Conventional 61.9 26.7 0.2 0.1 5/5 1.30E-05 11 5/5 Clustered Yes 
WARS-035 66-74 GLDEIDSAV mRNA splice 0.3 31.8 0.0 0.2 0/6 3.36E-07 0 2/6 Spread No 
 
STAR METHODS 
Contact for reagent and resource sharing 
Further information and requests for resources and reagents should be directed to and will be 
fulfilled by the Lead Contact, Roberto Mallone (roberto.mallone@inserm.fr). 
 
Experimental model and subject details 
Cell lines 
The ECN90 cell line (HLA-A*02:01/03:01, -B*40:01/49:01, -C*03:04/07:01) was derived 
from a human neonatal pancreas using described protocols (Ravassard et al., 2011). Cells 
were seeded in 15-cm diameter tissue culture dishes (Techno Plastic Products AG) coated 
with 0.1% fibronectin solution from human plasma (Sigma; 400 ng/cm²) and extracellular 
matrix from Engelbreth-Holm-Swarm murine sarcoma (Sigma; 1-2.4 mg/cm²). They were 
maintained in DMEM/F12 medium supplemented with 2% bovine serum albumin, 6.7 ng/ml 
sodium selenite, 10 mM nicotinamide, 50 µM β-mercaptoethanol and penicillin/streptomycin. 
IFN-γ (R&D) was added to the cell culture at 80-90% confluence at a final concentration of 
500 U/ml for 16-18 h. IFN-γ, TNF-α and IL-1β (all from R&D) were added at a final 
concentration of 2,000 U/ml, 1,100 U/ml, and 1,000 U/ml, respectively. 
Primary human tissues and PBMCs 
For HLA-I peptidomics experiments, transplantation-grade, undispersed primary human islets 
(75% purity; HLA-A*02:01/25:01, -B*39:01/51:01, -C*12:03/14:02) were obtained from a 
brain-dead non-diabetic organ donor (age 49 years, male, BMI 37 kg/m2; protocol approved 
by the Agence de la Biomédecine) with standard procedures and maintained in CMRL 1066 
medium (Sigma) supplemented with 10% fetal bovine serum. For RNAseq analyses, primary 
human islets from 5 brain-dead non-diabetic organ donors (mean age 50.6±10.2 years, 3 
females, 2 males, BMI 25±2 kg/m2; 57±5% β cells; protocol approved by the Ethics 
 
Committee of the University of Pisa, Italy) were exposed or not to IFN-γ (1,000 U/ml) and 
IL-1β (50 U/ml) for 48 h. For HLA-I expression analyses (Fig. 2G), primary human islets 
were from 3 non-diabetic organ donors (mean age 54.7±14.3 years, 1 female, 2 males, BMI 
29±5 kg/m2; protocol approved by the Ethics Committee of the University of Pisa, Italy). 
Primary human HLA Class IIlo and Class IIhi mTECs were purified as described (Pinto et al., 
2014) from the thymi of 3 children (male gender, age 6 days, 4 months and 9 months) 
undergoing corrective cardiac surgery at the University of Heidelberg, Germany (Ethics 
approval 367/2002). Blood was drawn into 9 ml sodium heparin tubes from T1D and healthy 
donors (Table S4) under the Ethics approval DC-2015-2536 Ile-de-France I. Informed consent 
was obtained from all subjects, or next-of-kin for islet donors. For in-situ MMr staining, 
pancreas and PLN sections were provided by nPOD. 
 
Method details 
Purification of pHLA-I complexes 
W6/32 and HC10 anti-HLA-I mAbs were purified on a protein A Prosep Ultraplus column 
(Millipore) from hybridoma supernatants. The W6/32 mAb recognizes a conformational 
epitope formed by the interaction of the HLA-I heavy chain and β2-microglobulin and was 
used for purifying pHLA-I complexes and for flow cytometry in conjunction with an FITC-
conjugated goat anti-mouse Ig Ab (BD). The HC10 mAb recognizes a linear epitope on the 
HLA-I heavy chain and was used for Western blotting along with an anti-α-tubulin mAb for 
loading control (Fig. 1B). Since α-tubulin expression is higher in ECN90 β cells than in 
primary islets, an anti-β-actin mAb was used for loading control to compare HLA-I 
expression and upregulation between the two cell types (Fig. 2G). To this end, the membrane 
previously probed for HLA-I (45 kD) was stripped and reprobed for β-actin (42 kD).    
 
The HLA-I peptidome of the ECN90 β-cell line was obtained from 5 biological replicates. A 
single biological replicate was available for primary human islets. Frozen cell pellets 
(~20x106/condition for ECN90 cells; ~25,000 islet equivalents/condition for primary islets, 
corresponding to ~19x106 β cells) were resuspended in a buffer containing 10 mM Tris-HCl 
pH 8.0, 150 mM NaCl, 5 mM EDTA, 0.1% (v/v) Complete Protease Inhibitor Cocktail 
(Roche), and 1% (w/v) octyl-β-D glucopyranoside (Sigma). Lysis was carried out at 4°C for 1 
h under rotation, with two sonication steps at 30 and 60 min. Lysates were cleared by 
centrifugation and pHLA-I complexes immunoaffinity-purified with the W6/32 mAb 
covalently bound to Protein A Sepharose CL-4B beads (GE Healthcare) by dimethyl 
pimelimidate cross-linking. Beads were subsequently loaded on GELoader Tips (20 µl; 
ThermoFisher) and washed before elution of pHLA-I complexes with 10% acetic acid. 
Aliquots were collected at each washing and elution step for analysis by 12% SDS-PAGE and 
Western blot using the HC10 mAb to verify the yield and purity of the eluted HLA-I. 
Eluted peptides and the associated HLA-I heavy chain and β2-microglobulin obtained from 
20x106 cells were concentrated to 20 µl by vacuum centrifugation, acidified with 10 µl of 1% 
formic acid (Normapur) and loaded on C18 stage tips (ThermoFisher) prewashed with 100% 
methanol and equilibrated with 2% acetonitrile (ACN) in 0.1% formic acid in LC-MS grade 
water. After loading, the C18 stage tips were washed with 2% ACN/0.1% formic acid and 
peptides separated from the HLA-I heavy chain and β2-microglobulin species by eluting them 
with 50% ACN/0.1% formic acid. The ACN was evaporated by vacuum centrifugation and 
the peptides resuspended up to 6 µl of volume in a solution of 2% ACN/0.1% formic acid and 
spiked with 10 fmol/µl of a cytomegalovirus pp65 495-503 peptide (NLVPMVATV) as 
internal control. For LC-MS analysis, 5 µl of this peptide solution were used. 
LC-MS/MS 
 
Peptides were loaded and separated by a nanoflow HPLC (RSLC Ultimate 3000, Dionex) on a 
C18 Acclaim PepMap nanocolumn (50 cm length, 75 µm internal diameter; Dionex) coupled 
on-line to a nano-electrospray ionization Q Exactive HF mass spectrometer (ThermoFisher) 
with a glass emitter (New Objective). Peptides were eluted with a linear gradient of 2–50% 
buffer B (80% ACN, 0.05% formic acid) at a flow rate of 220 nl/min over 60 min at 35°C. 
Data was acquired using a data-dependent acquisition “Top 20” method. We acquired one 
full-scan MS spectrum at a resolution of 60,000 at 200 m/z with an automatic gain control 
(AGC) target value of 3x106 ions, followed by 10 MS/MS spectra in higher energy collisional 
dissociation mode on the 10 most intense ions at a resolution of 15,000 at 200 m/z with an 
AGC target value of 1x105 with a maximum injection time of 120 ms and a dynamic 
exclusion of 20 s. Unassigned precursor ion charge states and charge states >4 were excluded. 
The peptide match option was set to ‘preferred’. The resulting spectra were analyzed by 
MaxQuant (www.coxdocs.org) using a custom database comprising: a) the reference human 
proteome (Swiss-Prot/UniProt, up000005640, release December 2012); b) an in-house 
database containing 119,305 predicted peptide splice products (Berkers et al., 2015) from 
major known and candidate β-cell protein Ags (Fig. S1 and Data S1); and c) the predicted aa 
neo-sequences encoded by mRNA splice variants identified by RNASeq. The following 
parameters were set: enzyme specificity: unspecific; variable modifications: methionine, 
tryptophan and histidine oxidation (+15.99 Da), cysteine oxidation to cysteic acid (+47.98 
Da) and tryptophan conversion to kynurenine (+3.99 Da); maximum false discovery rate 5%. 
Since the MS identification was targeted on HLA-I-eluted peptides rather than on proteins, 
the protein false discovery rate parameter was set to 100%. The initial allowed mass deviation 
of the precursor ion was set to 10 ppm and the maximum fragment mass deviation was set to 
20 mDa. The “match between runs” option was enabled to match identifications across 
 
different replicates in a time window of 0.5 min and an initial alignment time window of 20 
min. 
RNAseq 
RNAs from 5 individual preparations of primary human islets exposed or not to IFN-γ and IL-
1β for 48 h and from HLA Class IIlo and Class IIhi human mTECs were sequenced on an 
Illumina HiSeq 2000 at high depth (coverage >150x106 reads, which is sufficient to detect 
>80% of slice variants). RNA sequencing reads were mapped to the human reference genome 
hg19 using TopHat 2 and the Gencode release 18 annotation dataset. Mapped reads were used 
to quantify abundance and analyse the differential expression of genes and transcripts using 
Flux Capacitor (Montgomery et al., 2010).  
HLA-I peptidomics and transcriptomics bio-informatics analysis 
Predicted HLA-I binding affinities for each nonamer peptide were visualized as sequence 
logo plots using Gibbs clustering (www.cbs.dtu.dk/services/GibbsCluster; Fig. 1D), and as 
heat maps (Fig. 1E) using the open-source script of Caron et al. (Caron et al., 2015). 
For conventional peptides, source proteins were selected with Perseus (www.coxdocs.org) 
based on: a) a non-ubiquitous expression pattern, based on the Human Protein Atlas 
(www.proteinatlas.org); b) a pancreas- and β-cell-enriched expression pattern, based on the 
Human Protein Atlas, the Human Protein Reference Database (www.hprd.org) and the Single-
Cell Gene Expression Atlas of Human Pancreatic Islets (http://sandberg.cmb.ki.se/pancreas). 
The bioinformatics analysis pipeline is detailed in Fig. 1G. The 3,544 peptides identified were 
first filtered based on inter-sample reproducibility (≥2 of 5 biological replicates; n=2,997, 
85%) and aa length (8-12 aa; n=2,795, 93%). For all peptides, the final filter was based on an 
enrichment in HLA-I-purified samples compared with mock-purified ones based on m/z peak 
intensity, which verified the specific association of the identified peptides with pHLA-I 
complexes. From this dataset, we identified: 
 
1) 217 (8%) peptides derived from ubiquitous proteins carrying PTMs (blue pipeline in Fig. 
1G), from which 99 (46%; Table S2) were enriched in HLA-I-purified samples. 
2) 15 (0.5%) peptide splice variants (brown pipeline in Fig. 1G; see Fig. S1 for the 
identification strategy), from which 10 (67%) were enriched in HLA-I-purified samples 
(listed in Table S1). 
3) The remaining 2,561 peptides (both conventional and PTM species derived from β-cell-
enriched proteins; red pipeline in Fig. 1G) were filtered by Perseus based on non-ubiquitous 
expression of their source proteins (n=411; 16%), using the Human Protein Atlas; and 
pancreas- and β-cell-enriched expression (n=139, 34%), using the Human Protein Atlas, the 
Human Protein Reference Database and the Single-Cell Gene Expression Atlas of Human 
Pancreatic Islets. Finally, the 86 (62%) remaining peptides were retained as enriched in HLA-
I-purified samples (listed in Table S1). 
4) mRNA splice variants (green pipeline in Fig. 1G; n=2, 0.1%; both enriched in HLA-
purified samples; listed in Table S1) were identified by analyzing the HLA-I peptidomics 
dataset against the predicted aa neo-sequences obtained from RNAseq analysis. For this 
RNAseq pipeline (dashed boxes in Fig. 1G), 53,280 mRNAs were filtered based on: 
a) A median RPKM>5 in islets, either under basal or inflammatory conditions, a cut-off 
selected based on the median RPKM of known islet Ags (islet expression filter; n=14,504, 
27%). 
b) A median RPKM<0.1 in mTECs (either HLA Class IIlo or Class IIhi), or a median RPKM 
fold-decrease>100 vs. islet (mTEC expression filter; n=908, 6%). 
c) A median RPKM fold-increase>10 in islets compared to 12 control tissues (adipose tissue, 
breast, colon, heart, kidney, liver, lung, lymph node, ovary, prostate, skeletal muscle, white 
blood cells), using the Illumina BodyMap 2.0 dataset (islet enrichment filter; n=166, 18%). 
 
Tissues of neuroendocrine origin (brain, testis, adrenal gland and thyroid) were excluded for 
this filtering. 
d) We subsequently focused our analysis on mRNA isoforms, as described (Eizirik et al., 
2012; Villate et al., 2014). The predicted translation products were aligned using MUSCLE 
3.8 (www.ebi.ac.uk/Tools/msa/muscle), and aa neo-sequences were defined by comparing the 
predicted aa sequence of each mRNA isoform with that of the reference mRNA, taking as 
reference the longest and/or most prevalent mRNA isoform in islets (neo-sequence generation 
filter; n=88, 53%). 
The 336 predicted aa neo-sequences obtained from these 88 mRNA variants were used to 
interrogate HLA-I peptidomics datasets and searched in parallel for: 
e) Potential HLA-A2 binders, based on their predicted HLA-A2 binding affinity (KD<100 nM 
by NetMHC 4.0; www.cbs.dtu.dk/services/NetMHC) and stability (half-life ≥1.5 h by 
NetMHCstab 1.0; www.cbs.dtu.dk/services/NetMHCstab-1.0) (predicted HLA-A2 binding 
filter; n=66, 20%). 
f) A 9-10-aa length (peptide length filter; n=43, 65%). 
g) A neo-sequence ≥3 aa (neo-sequence filter; n=39, 92%). 
Overall, this combined HLA-I peptidomics and transcriptomics analysis pipeline led to the 
identification of 99 in vitro PTM candidates from ubiquitous proteins (Table S2); 10 in vitro 
peptide splice candidates, 86 in vitro candidates from β-cell proteins (including PTM variants) 
and 2 in vitro mRNA splice candidates (Table S1); and 39 in silico mRNA splice candidates 
(Fig. S2I). PTM candidates were not further analyzed. The other candidates underwent 
additional filtering steps to focus subsequent studies on HLA-A2-restricted peptides. 
Predicted HLA-A2 binders were first selected in silico using NetMHC 4.0  and NetMHCstab 
1.0 (except for in silico mRNA splice candidates, which had already been filtered for 
 
predicted HLA-A2 binding in the same way), then in vitro for experimental HLA-A2 binding 
and, finally, for CD8+ T-cell recognition.    
HLA-A2 binding assays 
Peptide binding to HLA-A*02:01 was measured using the transporter associated with Ag 
processing (TAP)-deficient T2 cell line. TAP deficiency leads to defective translocation of 
endogenous peptides from the cytosol into the ER, leading to the expression of unstable, 
empty HLA-A*02:01 molecules on the cell surface. This expression is stabilized in the 
presence of HLA-A*02:01-binding peptides, resulting in a higher surface expression that can 
be monitored by flow cytometry. T2 cells were washed in RPMI medium and plated in round-
bottom 96-well plates at 0.2x106 cells/200 µl in the presence of 5 µg/ml β2-microglobulin. 
Peptides prepared in DMSO were sequentially diluted 4-fold in RPMI and added to final 
concentrations of 102.4 to 0.1 µM for 24 h at 37°C, 5% CO2. The HLA-A*02:01-binding 
peptide Flu MP58-66 (GILGFVFTL), and a non-binding peptide CHGA382-390 (HPVGEADYF) 
were included as positive and negative controls, respectively. After incubation, the cells were 
washed twice with ice-cold phosphate-buffered saline (PBS) and stained with the viability 
marker Live/Dead Red and mouse anti-HLA-A2 mAb BB7.2, followed by an Alexa Fluor 
488-labeled goat-anti-mouse IgG Ab (Interchim). Following acquisition on a BD Fortessa 
cytometer, results were analyzed by gating on viable cells and expressed as the median 
fluorescence intensity fold increase of the test peptide compared with the negative control 
peptide at the same concentration.  
HLA-A2 MMr assays 
All peptides were synthesized at >90% purity (Synpeptides). HLA-A2 MMrs were produced 
and used as described (Culina et al., 2018). Each pHLA-A2 complex was used at a final 
concentration of 8-27 nM and conjugated with fluorochrome-labeled streptavidin at a 1:4 
ratio. The combinatorial MMr panel was first set up by staining HLA-A2+ PBMCs with the 
 
same set of fluorescent streptavidin-labeled MMrs, all loaded with the Flu MP58-66 epitope. 
Compensations were set using fluorescence-minus-one samples (i.e. omitting one streptavidin 
at a time). The concentration of each fluorescent MMr was corrected for the variable staining 
index of each streptavidin, in order to obtain a distinct double-MMr+ population for each 
fluorochrome pair. The identification of the same MMr+ population by each pair validated the 
panel. PBMCs were isolated by density gradient centrifugation using 50 ml Leucosep® tubes 
(Greiner/Dominique Dutscher), washed twice in RPMI medium supplemented with AB 
human serum (Sigma), counted on a ThermoFisher Countess II automated counter and frozen 
in pre-chilled 10% DMSO solution in AIM-V medium (ThermoFisher) using CoolCell 
containers (Biocision) stored overnight at ‒80°C prior to transfer into liquid nitrogen. At 
thawing, PBMCs were immediately diluted in pre-warmed AIM-V medium. Following 
centrifugation and one additional wash in AIM-V, PBMCs were counted and rested in the 
presence of 50 nM dasatinib for 30 min at 37°C before magnetic depletion of CD8– cells 
(StemCell Technologies). Staining was performed for 20 min at 20°C in 20 µl PBS-dasatinib 
for 107 cells with the combinatorial double-coded MMr panels (Culina et al., 2018) detailed in 
Fig. 3, followed, without washing, by mAb and Live/Dead Aqua staining at 4°C for 20 min. 
After one wash, cells were acquired using a FACSAria III cytometer configured as detailed in 
Table S6. Candidate epitopes binding to HLA-A2 (Fig. S2) that did not yield any appreciable 
MMr staining provided negative controls for each panel. Data was analyzed with FlowJo 
software as described in Fig. 3. Cells were sequentially gated on small lymphocytes, singlets, 
live cells (Live/Dead Aqua–), CD3+CD8+ T cells and total PE+, PE-CF594+, APC+, BV650+, 
BV711+ and BV786+ MMr+ T cells. Using Boolean operators, these latter gates allowed to 
selectively visualize each double-MMr+ population by including only those events positive for 
the corresponding fluorochrome pair. For example, UCN31-9 MMr
+ cells (PE+PE-CF594+) 
were visualized by gating on events that were PE+PE-CF594+APC‒BV650‒BV711‒BV786‒. 
 
Events negative for all MMr fluorochromes (PE‒PE-CF594‒APC‒BV650‒BV711‒BV786‒) 
were represented in the same PE/PE-CF-594 dot plot to set the double-MMr+ gate, as shown 
in Fig. 4A-F. CD45RA and CCR7 staining was subsequently visualized by gating on these 
MMr+ cells. Each dot plot of Fig. 3B-C displays a color-coded overlay of each double-MMr+ 
fraction and of the MMr‒ population to visualize the separation of each epitope-reactive CD8+ 
T-cell fraction relative to the others. 
In-situ HLA-A2 MMr staining 
In-situ immunohistochemistry staining was performed as described (Culina et al., 2018). 
Unfixed, frozen sections were dried for 2 h, loaded with 1 μg of PE-labeled MMrs overnight 
at 4°C, washed gently with PBS and fixed in 2% paraformaldehyde for 10 min. After a further 
wash, endogenous peroxidase activity was blocked with 0.3% H2O2. Sections were then 
incubated serially with a rabbit anti-PE Ab (Abcam), horseradish peroxidase-conjugated 
swine anti-rabbit Ig (Dako) and 3,3'-diaminobenzidine tetrahydrochloride substrate 
(ThermoFisher). After a final wash, sections were counterstained with hematoxylin, 
dehydrated via sequential passages in 95-100% ethanol and xylene, mounted and analyzed 
using a Nikon Eclipse Ni microscope with NIS-Elements D software v4.40. 
In-situ immunofluorescence staining was performed similarly, but non-specific reactions were 
blocked with 5% goat serum for 2 h at room temperature before serial incubations with rabbit 
anti-PE Ab (1:250, 1.5 h at room temperature) and Alexa Fluor 594-conjugated goat anti-
rabbit IgG (ThermoFisher; 1:500, 1 h at room temperature). After a further wash, sections 
were incubated for 1 h at room temperature with rat anti-CD8 mAb (Abcam; 1:100) together 
with mouse anti-CD45RO mAb (BioLegend; 1:200) followed, after one wash, by one final 
incubation for 1 h at room temperature with Alexa Fluor 488-conjugated goat anti-rat IgG 
together with Alexa Fluor 647-conjugated goat anti-mouse IgG (1:500/each; both from 
 
ThermoFisher). After DNA counterstaining with DAPI, sections were mounted and analyzed 
using a Leica TCS SP5 confocal laser scanning microscope with LAS software v2.6.0.7266. 
 
Quantification and statistical analysis 
Statistical details of experiments can be found in the legends of each figure. A two-tailed 
p<0.05 cut-off was used to define statistical significance. 
 
Data and software availability 
The custom script used to predict peptide splice products is provided in Data S1. The islet 
RNAseq datasets have been deposited under GEO accession number GSE108413. The mTEC 






Data S1. Related to Fig. 1G-S1. In-house script used to predict peptide splice products. 
Data S2. Related to Fig. 1G. mTEC RNAseq dataset of mRNA isoforms expressed in human 
islets. 
Figure 1 Click here to download Figure Fig1.tif 
Figure 2 Click here to download Figure Fig2.tif 
Figure 3 Click here to download Figure Fig3.tif 
Figure 4 Click here to download Figure Fig4.tif 
Figure 5 Click here to download Figure Fig5.tif 
Figure 6 Click here to download Figure Fig6.tif 
 
 
KEY RESOURCES TABLE 
REAGENT or RESOURCE SOURCE IDENTIFIER 
Antibodies 
Mouse monoclonal anti-HLA Class I, clone W6/32 ATCC ATCC HB-95; RRID: 
CVCL_7872 
Mouse monoclonal anti-HLA Class I, clone HC10 Laboratory of 
Hidde L. Ploegh 
RRID: 
AB_2728622 




Mouse monoclonal anti-β-actin, clone AC-15 Sigma Cat#A5441; RRID: 
AB_476744 
Goat polyclonal Anti-mouse Ig (H+L) HRP SouthernBiotech Cat#1010-05; RRID: 
AB_2728714 
Mouse monoclonal anti-HLA-A2, clone BB7.2 ATCC ATCC HB-82; RRID: 
CVCL_7246 
Goat polyclonal anti-mouse Ig FITC BD Pharmingen Cat#554001; RRID: 
AB_395197 
Goat polyclonal anti-mouse IgG (H+L) Alexa Fluor 488 Interchim Cat#FP-SA4010; 
RRID: AB_2728715 




Mouse monoclonal anti-human CD3 APC-H7, clone SK7 BD Pharmingen Cat#560176; RRID: 
AB_1645475 
Mouse monoclonal anti-human CD8 PE-Cy7, clone 
RPA-T8 
BD Pharmingen Cat#557746; RRID: 
AB_396852 
Mouse monoclonal anti-human CD45RA FITC, clone 
HI100 
BD Pharmingen Cat#555488; RRID: 
AB_395879 
Mouse monoclonal anti-human CCR7 BV421, clone 
150503 
BD Horizon Cat#562555; RRID: 
AB_2728119 
LIVE/DEAD™ Fixable Aqua Dead Cell Stain Kit Thermo Fisher Cat#L34965 
LIVE/DEAD™ Fixable Red Dead Cell Stain Kit Thermo Fisher Cat# L23102 
Streptavidin PE BD Pharmingen Cat#554061; RRID: 
AB_10053328 
Streptavidin PE-CF594 BD Horizon Cat#562284; RRID: 
AB_11154598 
Streptavidin APC BD Pharmingen Cat#554067; RRID: 
AB_10050396 
Streptavidin BV650 BD Horizon Cat#563855 
Streptavidin BV711 BD Horizon Cat#563262 
Streptavidin BV786 BD Horizon Cat#563858 
Rabbit polyclonal anti-B phycoerythrin Abcam Cat#ab7011; RRID: 
AB_305700 
Swine polyclonal anti-rabbit Ig HRP  Dako Cat#P0217; RRID: 
AB_2728719 
Rat monoclonal anti-human CD8, clone YTC182.20 Abcam Cat#ab60076; RRID: 
AB_940921 
Mouse monoclonal anti-human CD45RO, clone UCHL1 BioLegend Cat#304202; RRID: 
AB_314418 
Goat polyclonal anti-rabbit IgG (H+L) Alexa Fluor 594 Thermo Fisher Cat#A-11037; RRID: 
AB_2534095 




Goat polyclonal anti-mouse IgG (H+L) Alexa Fluor 647 Thermo Fisher Cat# A-21236; 
RRID: AB_2535805 
Bacterial and Virus Strains  
   
Biological Samples   
Human pancreas unfixed frozen sections nPOD www.jdrfnpod.org 
Human pancreatic lymph node unfixed frozen sections nPOD www.jdrfnpod.org 
Chemicals, Peptides, and Recombinant Proteins 
HLA-A2 heavy chain ImmunAware N/A 
β2-microglobulin Lee Biosolutions Cat#126-11 
Dasatinib LC Laboratories Cat#D-3307 
Critical Commercial Assays 
   
Deposited Data 
Human reference proteome Swiss-Prot/UniProt, 




Human Protein Atlas v.13.0 Human Protein Atlas www.proteinatlas.org 
Human Protein Reference Database, release 9 Human Protein 
Reference Database 
www.hprd.org 












Human islet RNAseq This paper GEO # GSE108413 
Human mTEC RNAseq This paper Data S2 
Experimental Models: Cell Lines 
Human: ECN90 β-cell line Culina et al., 2018; 
Univercell Biosolutions 
N/A 
Human: T2 (174 x CEM.T2) cell line ATCC ATCC CRL-1992; 
RRID: CVCL_2211 
Mouse: W6/32 hybridoma cell line ATCC ATCC HB-95; RRID: 
CVCL_7872 
Mouse: HC10 hybridoma cell line Laboratory of 
Hidde L. Ploegh 
RRID: 
AB_2728622 
Mouse: BB7.2 hybridoma cell line ATCC ATCC HB-82; RRID: 
CVCL_7246 
Experimental Models: Organisms/Strains 
   
Oligonucleotides 
   
Recombinant DNA 
   
Software and Algorithms 
FlowJo v10 FlowJo, LLC www.flowjo.com 
 





Gibbs clustering v1.1 DTU Bioinformatics www.cbs.dtu.dk/serv
ices/GibbsCluster 
LAS v2.6.0.7266 Leica Microsystems N/A 




MUSCLE v3.8 EMBL-EBI www.ebi.ac.uk/Tools
/msa/muscle 
NetMHC v4.0 DTU Bioinformatics www.cbs.dtu.dk/serv
ices/NetMHC 
NetMHCstab v1.0 DTU Bioinformatics www.cbs.dtu.dk/serv
ices/NetMHCstab-
1.0 
NetMHCStabPan v1.0 DTU Bioinformatics www.cbs.dtu.dk/serv
ices/NetMHCstabpa
n 
NIS-Elements D v4.40 Nikon N/A 
   




Python and R Scripts Caron et al., 2015 https://elifesciences.
org/articles/07661/fig
ures#SD9-data 
Script for the prediction of peptide splice products This paper Data S1 
   











Figure S1. Related to Fig. 1G. Schematic of the strategy used for predicting peptide splice 
variants.  
Figure S2. Related to Fig. 4. HLA-A2 binding measurements for the β-cell peptides selected 
for CD8+ T-cell validation.  
Fig. S3. Related to Fig. 6. Screening of HLA-A2-restricted peptide reactivities in pancreas-
infiltrating cells from a T1D case.  
Table S1. Related to Fig 1G, 2A-E. List of the 98 HLA-I-bound peptides identified in 
ECN90 β cells. 
Table S2. Related to Fig 1G. List of the 99 HLA-I-bound PTM peptides originating from 
ubiquitous proteins identified in ECN90 β cells.  
Table S3. Related to Fig 2F. List of the 33 HLA-I-bound peptides identified in primary human 
islets.  
Table S4. Related to Fig. 4-5. Characteristics of HLA-A2+ study subjects for ex-vivo MMr 
studies on PBMCs.  
Table S5. Related to Fig. 6. nPOD cases analyzed by in-situ tissue MMr staining.  
Table S6. Related to STAR Methods. Configuration of the flow cytometer used for HLA-A2 
MMr assays. 
Data S1. Related to Fig. 1G-S1. In-house script used to predict peptide splice products. 
Data S2. Related to Fig. 1G. mTEC RNAseq dataset of mRNA isoforms expressed in human 
islets. 
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Figure S1. Related to Fig. 1G. Schematic of the strategy used for predicting peptide splice variants. 
The indicated known or putative β-cell Ags (first column; PPI, IGRP, CHGA, SCG5, PTPRN/IA-2, NPY, 
SLC30A8/ZnT8, IAPP, PCSK2, GAD2/GAD65) were scanned with an in-house Python script (Data S1) 
based on reported peptide splicing preferences (Berkers et al., 2015) for the presence of the indicated N- 
and C-terminal preferred precursor sequences (second and third column, respectively, where Φ indicates 
any hydrophobic aa residue). Each N-terminal precursor sequence identified was then combined with each 
C-terminal precursor sequence, derived either from the same protein (cis-splicing) or from a different 
protein (trans-splicing). An example is shown for PPI and IGRP. The 119,305 predicted peptide splice 
sequences thus obtained (26,396 cis-spliced and 92,909 trans-spliced) were saved in FASTA format and 
appended to the Swiss-Prot human proteome database used for assigning aa sequences to the identified MS 
spectra with the MaxQuant algorithm. 
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Figure S2. Related to Fig. 4. HLA-A2 binding measurements for the β-cell peptides selected for CD8+ 
T-cell validation. (A-F) Flow cytometry measurement of peptide binding to HLA-A2 using TAP-deficient 
T2 cells. T2 cells were pulsed with the indicated peptides at 4-fold sequential dilutions (102.4 to 0.1 μM) at 
37°C and stained for HLA-A2. Representative stains at 0.4, 6.4 and 102.4 μM are shown for peptides that 
are weak binders (IAPP15-17/5-10; A), intermediate binders (SCG5-009186-194; B), strong binders (PCSK230-38; 
C) and non-binders (GAD2257-265; D), along with the non-binding (ChgA382-390; E) and binding (Flu MP58-66; 
F) control peptides included in each assay. G. Plotting of relative median fluorescence intensity values 
(arbitrary units, AU) for all peptide dilutions normalized to the non-binding ChgA382-390 control peptide. 
Representative examples of two independent experiments are shown. (H-I) Summary of the HLA-A2 
binding values measured for the β-cell peptides selected from the in vitro HLA-I peptidomics (H) and in 
silico RNAseq pipeline (I) using the T2 assays depicted in panels A-G. The relative median fluorescence 
intensity measured at 25.6 and 102.4 µM peptide concentrations is shown along with their relative ranking: 
‒ (<1.50 AU); + (1.50-1.99 AU); ++ (2-2.49 AU); +++ (≥2.50 AU). The in silico predicted HLA-A2 
binding affinity (NetMHC 4.0) and stability values (NetMHCstab 1.0) are also shown. Peptides in bold red 
fonts bound HLA-A2 and were retained for CD8+ T-cell validation, with those eventually validated (see Fig. 
4) highlighted in grey. In panel H, the GAD2257-265 peptide eluted from ECN90 cells with a predicted HLA-
A3 restriction is included as negative control. For β-cell peptides selected from the in silico RNAseq 
pipeline (panel I), RPKM values of the source mRNA splice variant in control- and cytokine-treated islets 
are shown in the last two columns. The color codes indicate no change in mRNA expression (<2 log2 fold-
change, either positive or negative; green), an increase for cytokine-treated islets (≥+2 log2 fold-change; red) 




Fig. S3. Related to Fig. 6. Screening of HLA-A2-restricted peptide reactivities in pancreas-
infiltrating cells from a T1D case. Pancreas sections from T1D EUnPOD case #060217 (39-year-old 
female, T1D duration 21 years, positive for anti-GAD aAbs) were immunohistochemically stained in situ 
with the following MMrs: IAPP15-17/5-10 (A-B), ISL1276-284 (C-D), SCG5-009186-194 (E-F), UCN31-9 (G-H) 
and the positive control PPI6-14 (I-J). For each MMr, pancreas images at 20X magnification are shown on 
the left (scale bar 100 μm), and higher magnifications of the dotted areas are shown on the right (scale bar 
36 μm).  
 
Source protein(s) Accession number(s) Amino acid positions Sequence HLA restriction Predicted affinity (nM) Predicted stability (h) IFN‐γ (%) IFN‐γ/TNF‐α/IL‐1β (%) Basal (%) IFN‐γ log2 FC IFN‐γ/TNF‐α/IL‐1β log2 FC
ABCC8 Q09428 611‐619 SEFLSSAEI B*40:01 46.5 1.6 20 80 0 IFN‐γ only IFN‐γ/TNF‐α/IL‐1β only
ABCC8 Q09428 787‐795 IIFESPFNK A*03:01 15.6 2.2 80 60 0 IFN‐γ only IFN‐γ/TNF‐α/IL‐1β only
AMPH P49418 459‐467 EEPVEEAVI B*40:01 3182.1 0.3 80 40 40 2.64 4.25
AP3B2 Q13367 403‐411 NETNIPTVL B*40:01 44.7 1.3 40 40 0 IFN‐γ only IFN‐γ/TNF‐α/IL‐1β only
C1QL1;C1QL4 Q86Z23;O75973 196‐204 ASNSVILHL C*03:04 837.2 0.2 100 80 20 4.85 4.19
CADPS;CADPS2 Q86UW7;Q9ULU8 780‐788 SLLERVLMK A*03:01 27.6 5.1 20 60 20 ‐2.34 3.38
CADPS;CADPS2 Q86UW7;Q9ULU8 780‐788 SLLERVLM(+15.99)K A*03:01 27.6 5.1 60 0 20 3.34 Basal only
CHGA P10645 2‐10 RSAAVLALL C*03:04 568.9 0.3 40 80 40 3.87 6.16
CHGA P10645 120‐130 AVEEPSSKDVM(+15.99) C*03:04 3119.5 0.2 40 100 40 ‐2.25 5.27
CHGA P10645 120‐131 AVEEPSSKDVM(+15.99)E NA NA NA 40 60 60 0.58 ‐1.17
CHGA P10645 121‐130 VEEPSSKDVM B*40:01 781.2 0.5 0 60 80 Basal only 0.81
CHGA P10645 121‐131 VEEPSSKDVM(+15.99)E NA NA NA 60 40 20 4.35 2.28
CHGA P10645 344‐352 KMDQLAKEL A*02:01 543.8 0.6 0 60 80 Basal only ‐2.08
CHGA P10645 344‐354 KMDQLAKELTA A*02:01 823.2 0.6 100 100 40 ‐1.08 2.45
CHGA P10645 344‐354 KM(+15.99)DQLAKELTA A*02:01 823.2 0.6 0 0 40 Basal only Basal only
CHGA P10645 344‐355 KMDQLAKELTAE NA NA NA 20 100 80 ‐3.38 2.06
CHGA P10645 380‐389 AYGFRGPGPQ NA NA NA 0 40 60 Basal only ‐5.55
CHGA P10645 381‐390 YGFRGPGPQL C*03:04 38.0 0.2 100 80 40 2.91 2.15
CHGA P10645 383‐390 FRGPGPQL C*07:01 305.3 0.1 60 100 0 IFN‐γ only IFN‐γ/TNF‐α/IL‐1β only
CHGA P10645 402‐409 SLEAGLPL A*02:01 300.4 0.8 0 40 20 Basal only 1.34
CHGA P10645 402‐411 SLEAGLPLQV A*02:01 115.1 1.3 100 100 0 IFN‐γ only IFN‐γ/TNF‐α/IL‐1β only
CHGA P10645 403‐411 LEAGLPLQV B*40:01, B*49:01 402.0, 343.9 0.8, 0.7 100 80 0 IFN‐γ only IFN‐γ/TNF‐α/IL‐1β only
CHGB P05060 603‐613 RVAQLDQLLHY A*03:01 641.8 0.9 40 80 40 ‐1.04 0.32
CPE P16870 83‐91 FEGRELLVI B*40:01, B*49:01 223.1, 264.4 0.6, 0.4 100 100 0 IFN‐γ only IFN‐γ/TNF‐α/IL‐1β only
CPE/PTPRN;CPE/PTPRN;CPE/PTPRN P16870/Q16849;P16870/Q16849;P16870/Q16849 61‐66/133‐135;61‐66/28‐30;61‐66/949‐951 EALVSV/RPG NA NA NA 80 20 0 IFN‐γ only IFN‐γ/TNF‐α/IL‐1β only
DLK1 P80370 4‐12 TEALLRVLL B*40:01 20.4 1.3 60 80 0 IFN‐γ only IFN‐γ/TNF‐α/IL‐1β only
ESRRG P62508 361‐369 LEKEEFVTL B*40:01 45.5 0.9 80 80 0 IFN‐γ only IFN‐γ/TNF‐α/IL‐1β only
FAM171B Q6P995 19‐28 VLLKARLVPA A*02:01 148.8 2.4 60 100 40 ‐0.24 0.69
GAD2 Q05329 257‐265 KM(+15.99)FPEVKEK A*03:01 48.0 4.7 40 0 0 IFN‐γ only NA
GAD2/GAD2 Q05329/Q05329 97‐104/460‐462 LLPAC(+47.98)DGERAK A*03:01 3984.3 0.3 60 20 20 2.00 ‐1.64
GPR119 Q8TDV5 48‐56 AVADTLIGV A*02:01 9.3 3.2 20 80 0 IFN‐γ only IFN‐γ/TNF‐α/IL‐1β only
HSFY1 Q96LI6 143‐151 FSKIQQNFQ NA NA NA 60 80 0 IFN‐γ only IFN‐γ/TNF‐α/IL‐1β only
HSPA5/HSPA5 P11021/P11021 215‐220/74‐76 EGEKNIRLI NA NA NA 0 100 0 Not detected IFN‐γ/TNF‐α/IL‐1β only
IAPP/IAPP;PTPRN/IAPP P10997/P10997;Q16849/P10997 15‐17/5‐10;596‐598/5‐10 VAL/KLQVFL C*03:04, A*02:01 612.5, 3599.1 0.2, 0.5 100 80 40 1.88 1.98
IGF2BP3 O00425 552‐560 KIQEILTQV A*02:01 20.5 9.3 60 100 0 IFN‐γ only IFN‐γ/TNF‐α/IL‐1β only
INA Q16352 170‐178 GLAEEVQRL A*02:01 30.7 2.3 80 20 20 3.04 1.68
INS P01308 2‐10 ALWMRLLPL A*02:01 26.7 5.6 0 40 0 Not detected IFN‐γ/TNF‐α/IL‐1β only
INS P01308 2‐10 ALW(+3.99)M(+15.99)RLLPL A*02:01 26.7 5.6 100 80 40 3.75 1.60
INS P01308 6‐14 RLLPLLALL A*02:01 11.6 8.0 80 60 0 IFN‐γ only IFN‐γ/TNF‐α/IL‐1β only
INS P01308 15‐24 ALWGPDPAAA A*02:01 95.5 1.8 80 100 20 ‐0.91 3.80
INS P01308 15‐24 ALW(+3.99)GPDPAAA A*02:01 95.5 1.8 60 100 80 ‐1.83 2.02
INS P01308 15‐24 ALW(+15.99)GPDPAAA A*02:01 95.5 1.8 20 60 60 ‐4.27 ‐0.57
INS P01308 15‐26 ALWGPDPAAAFV A*02:01 8.2 6.6 0 60 0 Not detected IFN‐γ/TNF‐α/IL‐1β only
INS P01308 29‐38 HLC(+47.98)GSHLVEA A*02:01 521.1 1.5 60 0 40 1.40 Basal only
INS P01308 34‐42 HLVEALYLV A*02:01 3.3 17.8 100 100 0 IFN‐γ only IFN‐γ/TNF‐α/IL‐1β only
INS P01308 56‐66 REAEDLQVGQV B*40:01 127.8 1.0 0 60 0 Not detected IFN‐γ/TNF‐α/IL‐1β only
INS P01308 58‐66 AEDLQVGQV B*40:01 964.8 0.6 100 100 40 2.25 3.54
INS P01308 58‐68 AEDLQVGQVEL B*40:01 36.1 1.5 80 60 40 4.69 4.94
INS‐006 INS‐006 56‐65 REAEDLQGSL B*40:01 9.9 1.4 20 60 0 IFN‐γ only IFN‐γ/TNF‐α/IL‐1β only
INS/PTPRN P01308/Q16849 15‐21/437‐439 ALWGPDP/KVN NA NA NA 40 100 20 ‐1.22 2.27
INS/SLC30A8 P01308/Q8IWU4 15‐20/30‐33 ALWGPD/KPVN NA NA NA 40 40 80 0.18 ‐2.22
ISL1 P61371 276‐284 GLQANPVEV A*02:01 82.6 2.4 100 0 0 IFN‐γ only NA
JAKMIP2;JAKMIP3 Q5VZ66;Q96AA8 31‐39 KLTDIQIEL A*02:01 8.3 6.2 0 80 0 Not detected IFN‐γ/TNF‐α/IL‐1β only
KCNK16 Q96T55 129‐137 ALLGIPLNV A*02:01 11.5 3.8 40 40 0 IFN‐γ only IFN‐γ/TNF‐α/IL‐1β only
KCNK16 Q96T55 13‐21 RVLPLLLAY A*03:01 150.3 0.5 80 100 0 IFN‐γ only IFN‐γ/TNF‐α/IL‐1β only
KIF1A;KIF1B;KIF1C Q12756;O43896;O60333 153‐161 RVRDLLNPK A*03:01 138.5 6.6 100 80 20 3.72 4.53
KIF1A Q12756 219‐228 AVFNIIFTQK A*03:01 24.9 5.0 80 80 40 4.40 5.01
KIF1A;KIF1B Q12756;O60333 734‐743 KEANAISVEL B*40:01 10.6 2.6 0 60 0 Not detected IFN‐γ/TNF‐α/IL‐1β only
KIF1A Q12756 796‐805 ATHYWTLEKL C*03:04 1925.8 0.2 20 100 0 IFN‐γ only IFN‐γ/TNF‐α/IL‐1β only
KIF1A Q12756 860‐868 LLYPVPLVH A*03:01 119.8 0.6 60 100 60 2.37 3.46
KIF1A Q12756 877‐885 GEVKGFLRV B*40:01 106.6 0.7 40 100 60 2.87 5.02
KIF1A Q12756 1347‐1355 VLDTSVAYV A*02:01 6.3 8.3 60 100 20 3.01 4.39
KIF1A Q12756 1480‐1488 KLSEMSVTL A*02:01 6.9 6.2 40 20 0 IFN‐γ only IFN‐γ/TNF‐α/IL‐1β only
KIF1A Q12756 1480‐1488 KLSEM(+15.99)SVTL A*02:01 6.9 6.2 40 40 40 0.71 ‐0.54
MYO3A Q8NEV4 1517‐1525 SIQEEKRRP NA NA NA 0 40 20 Basal only 3.00
NEUROD1 Q13562 291‐299 AEFEKNYAF B*40:01 19.9 1.7 60 100 0 IFN‐γ only IFN‐γ/TNF‐α/IL‐1β only
NPC1L1 Q9UHC9 1158‐1167 LGLDLRSGLL C*03:04 4828.2 0.1 20 80 0 IFN‐γ only IFN‐γ/TNF‐α/IL‐1β only
NPY/PTPRN;NPY/SCG5 P01303/Q16849;P01303/P05408 13‐18/166‐168;13‐18/488‐490 TLALSL/KLL A*02:01 754.6 0.7 80 40 0 IFN‐γ only IFN‐γ/TNF‐α/IL‐1β only
PCSK1 P29120 517‐525 RRGDLHVTL C*07:01 204.5 0.1 100 20 0 IFN‐γ only IFN‐γ/TNF‐α/IL‐1β only
PCSK1 P29120 706‐714 KLNKPSQLK A*03:01 16.9 13.1 40 100 60 ‐0.50 1.09
PCSK2 P16519 30‐38 FTNHFLVEL A*02:01, C*03:04 43.4, 40.0 2.6, 0.4 60 80 20 7.12 6.78
PCSK2/PTPRN;PCSK2/PTPRN P16519/Q16849;P16519/Q16849 479‐483/70‐73;479‐483/885‐888 IPSTG/RPLL C*03:04 2916.3 0.2 60 100 20 1.39 3.49
PDX1 P52945 109‐117 LEEPNRVQL B*40:01 62.2 0.9 20 40 0 IFN‐γ only IFN‐γ/TNF‐α/IL‐1β only
PEG10 Q86TG7 158‐166 FEDPQRREV B*40:01 1731.7 0.4 100 100 80 1.35 2.77
PEG10 Q86TG7 380‐388 HEYVAQNGI B*40:01 87.0 1.0 20 80 20 1.23 4.21
PIK3R3;PIK3R1 Q92569;P27986 144‐152;412‐420 SLAQYNPKL A*02:01 22.0 4.2 80 80 0 IFN‐γ only IFN‐γ/TNF‐α/IL‐1β only
PIK3R3 Q92569 289‐298 REIDKKMNSI B*40:01 140.5 1.1 0 80 0 Not detected IFN‐γ/TNF‐α/IL‐1β only
PNMA2 Q9UL42 50‐58 RLLGKIFRK A*03:01 16.3 10.0 100 100 80 2.04 2.70
PNMA2 Q9UL42 247‐255 RRTAQVRYL C*07:01 48.0 0.1 100 100 40 4.33 4.91
PRPH P41219 171‐179 GLAEDLAAL A*02:01 7.2 2.5 60 40 0 IFN‐γ only IFN‐γ/TNF‐α/IL‐1β only
PRPH P41219 377‐385 REYQELLNV B*49:01 59.8 1.0 20 80 20 4.42 6.35
PTPRN Q16849 156‐164 RLPQPPVGK A*03:01 326.7 2.1 80 100 40 2.65 3.31
PTPRN Q16849 509‐516 VVGPALTF C*03:04 1908.4 0.1 40 80 0 IFN‐γ only IFN‐γ/TNF‐α/IL‐1β only
PTPRN;PTPRN2 Q92932;Q16849 965‐975 AVAEEVNAILK A*03:01 213.0 3.5 80 100 0 IFN‐γ only IFN‐γ/TNF‐α/IL‐1β only
PTPRN/PTPRN Q16849/Q16849 576‐580/708‐711 SVLLT/RLAK A*03:01 84.2 1.6 0 60 40 Basal only 1.63
RTN1 Q16799 120‐129 STYFTGILQK A*03:01 17.0 4.7 100 100 0 IFN‐γ only IFN‐γ/TNF‐α/IL‐1β only
SCG3 Q8WXD2 166‐174 AVFDKIVSK A*03:01 37.7 4.7 40 80 0 IFN‐γ only IFN‐γ/TNF‐α/IL‐1β only
SCG5 P05408 182‐191 SVNPYLQGQR A*03:01 1543.4 0.4 60 80 40 ‐1.47 ‐0.01
SCG5 P05408 182‐192 SVNPYLQGQRL C*03:04 785.6 0.2 100 40 20 0.58 ‐0.78
SCG5 P05408 186‐196 YLQGQRLDNVV A*02:01 151.8 1.7 0 0 40 Basal only Basal only
SCG5‐009 SCG5‐009 193‐201 RLKPSLVGK A*03:01 25.5 13.6 60 0 0 IFN‐γ only NA
SLC30A8 Q8IWU4 6‐16 RTYLVNDKAAK A*03:01 38.7 7.3 100 100 100 0.35 1.99
SLC30A8/NPY;SLC30A8/CHGA Q8IWU4/P01303;Q8IWU4/P10645 16‐21/90‐92;16‐21/357‐359 KMYAFT/RLE A*03:01 803.0 0.4 20 80 40 ‐1.02 3.30
ST18 O60284 304‐312 SLLEQAIAL A*02:01 8.2 2.9 80 80 0 IFN‐γ only IFN‐γ/TNF‐α/IL‐1β only
SYP P08247 69‐77 VEFEYPFRL B*40:01 28.1 1.4 60 60 0 IFN‐γ only IFN‐γ/TNF‐α/IL‐1β only
UBE2QL1 A1L167 23‐31 SLFDWNVKL A*02:01 3.8 4.4 40 40 0 IFN‐γ only IFN‐γ/TNF‐α/IL‐1β only
UCN3 Q969E3 1‐9 MLMPVHFLL A*02:01 2.5 12.2 0 100 40 Basal only 3.28
UCN3 Q969E3 46‐56 GQWEDASLLSK A*03:01 425.9 1.4 0 40 0 Not detected IFN‐γ/TNF‐α/IL‐1β only
Table S1. Related to Fig 1G, 2A-E. List of 
the 98 HLA-I-bound peptides identified in 
ECN90 β cells. The bioinformatics filters 
depicted in Fig. 1G were applied and the β-cell-
enriched (n=86; conventional and with PTMs), 
peptide splice (n=10) and mRNA splice (n=2) 
aa sequences identified are listed in the 
alphabetical order of their source proteins. 
HLA-I restrictions were assigned based on the 
top scores of predicted affinity and stability, as 
determined by NetMHCstabpan 
(www.cbs.dtu.dk/services/NetMHCstabpan). 
The percent of positive biological replicates out 
of 5 analyzed are listed for IFN-γ-treated, IFN-
γ/TNF-α/IL-1β-treated and untreated (basal) 
ECN90 β cells. The last two columns display 
the log2 median fold change (FC) in peptide 
content for IFN-γ vs. basal and IFN-γ/TNF-
α/IL-1β vs. basal conditions, respectively. The 
color codes indicate no change (<2 log2 FC, 
either positive or negative; green), an increase 
for cytokine-treated conditions (≥+2 log2 FC; 
red) or a decrease for cytokine-treated 
conditions (≤‒2 log2 FC; blue). HLA-A2-
restricted peptides in bold red fonts were 
further analyzed for their recognition by CD8+ 
T cells, with those eventually validated as 
recognized by the naïve CD8+ T-cell repertoire 
(see Fig. 4) highlighted in grey. The remaining 
HLA-A2-restricted peptides were excluded 
because they were either length variants of 
peptides with better affinity scores or β-cell 
epitopes already described in the literature, i.e. 
PPI2-10, PPI6-14, PPI15-24, PPI29-38 (INSB5-14), 
PPI34-42 (INSB10-18). The PTM peptides 
identified as originating from ubiquitous 
proteins are listed separately in Table S2. NA, 
not available. 
 
Source protein(s) Accession number(s) Amino acid positions Sequence HLA restriction Predicted affinity (nM) Predicted stability (h) IFN‐γ (%) IFN‐γ/TNF‐α/IL‐1β (%) Basal (%) IFN‐γ log2 FC IFN‐γ/TNF‐α/IL‐1β log2 FC
AAMP Q13685 150‐159 ATGDM(+15.99)SGLLK A*03:01 253.54 2.0 40 40 20 0.09 ‐0.63
ABCB1 P08183 442‐453 RLYDPTEGM(+15.99)VSV A*02:01 5.4 13.3 60 40 0 IFN‐γ only IFN‐γ/TNF‐α/IL‐1β only
ACTN4 O43707 809‐817 AEFNRIM(+15.99)SL B*40:01 17.6 1.9 0 0 40 Basal only Basal only
AP1M2 Q9Y6Q5 30‐38 IEHFM(+15.99)PLLV B*40:01, B*49:01 263.3, 147.7 0.8, 0.9 40 0 20 1.52 Basal only
APOL6 Q9BWW8 85‐93 AVISGVM(+15.99)SL C*03:04, A*02:01 98.9, 22.3 1.3, 0.3 40 0 20 2.49 Basal only
ARMCX1 Q9P291 379‐387 KEW(+3.99)DREILL B*40:01 26.5 1.4 100 80 0 IFN‐γ only IFN‐γ/TNF‐α/IL‐1β only
ASXL1 Q8IXJ9 327‐335 GEFTHEM(+15.99)QV B*40:01 103.4 1.1 40 0 20 3.16 Basal only
ATP6V0B Q99437 136‐144 SM(+15.99)FGAGLTV A*02:01 14.3 2.6 20 40 40 1.32 ‐0.51
BRD8 Q9H0E9 770‐778 AEFQRDIM(+15.99)L B*40:01 18.2 1.7 20 20 100 ‐3.14 ‐4.80
BUB1B O60566 745‐753 IEDRPM(+15.99)PKL B*40:01 141.3 0.8 80 80 0 IFN‐γ only IFN‐γ/TNF‐α/IL‐1β only
C16orf62 Q7Z3J2 929‐937 RTM(+15.99)VKTLEY A*03:01 98.7 1.8 60 40 0 IFN‐γ only IFN‐γ/TNF‐α/IL‐1β only
CCNB1 P14635 204‐212 ILIDW(+3.99)LVQV A*02:01 2.2 56.6 40 0 20 0.45 Basal only
CCT8 P50990 296‐304 KVADM(+15.99)ALHY A*03:01 122.4 2.0 40 0 0 IFN‐γ only Not detected
CDC73 Q6P1J9 313‐321 GTYHGM(+15.99)TLK A*03:01 12.5 13.4 0 60 0 Not detected IFN‐γ/TNF‐α/IL‐1β only
COPG1;COPG2 Q9Y678;Q9UBF2 307‐317 AVRTLNKVAM(+15.99)K A*03:01 227.0 1.0 100 0 0 IFN‐γ only Not detected
COX11 Q9Y6N1 244‐252 AEDPRM(+15.99)IKV B*40:01, B*49:01 1308.6, 1530.9 0.7, 0.6 60 80 60 0.44 ‐0.53
CTNNA1 P35221 898‐906 SEFKAM(+15.99)DSI B*40:01 29.9 1.0 60 40 40 1.54 ‐0.68
CTNNB1 P35222 186‐194 HAIM(+15.99)RSPQM C*03:04 30.3 0.3 60 20 40 0.21 ‐2.92
DEGS1 O15121 83‐91 SM(+15.99)TLAIHEI A*02:01 66.9 4.5 40 0 20 0.38 Basal only
DES;INA;NEFH;NEFM;VIM Q16352;P17661;P07197;P12036;P08670 377‐387 REYQDLLNVKM(+15.99) B*40:01 25.3 1.7 40 40 40 0.62 ‐0.30
DHX8 Q14562 981‐989 AEFPLEPM(+15.99)L B*40:01 9.6 1.8 80 20 80 2.68 ‐5.37
DSP P15924 2792‐2802 SM(+15.99)VEDITGLRL A*02:01 69.6 0.9 20 0 40 ‐0.71 Basal only
EIF4G1 Q04637 719‐727 VLM(+15.99)TEDIKL A*02:01 86.7 1.6 40 0 20 2.21 Basal only
FAM136A Q96C01 8‐18 RVQEAVESM(+15.99)VK A*03:01 331.7 5.7 0 0 40 Basal only Basal only
FBXO21 O94952 417‐425 AM(+15.99)YPDQVQL A*02:01 32.3 1.7 20 40 0 IFN‐γ only IFN‐γ/TNF‐α/IL‐1β only
G3BP1 Q13283 106‐114 RRFM(+15.99)QTFVL C*07:01 61.4 0.2 20 40 40 ‐4.14 ‐0.64
GNAS Q5JWF2;P63092 752‐762 AM(+15.99)SNLVPPVEL A*02:01 41.0 1.9 100 100 40 3.89 3.26
GNAS Q5JWF2;P63092 795‐804 ALW(+3.99)EDEGVRA A*02:01 106.1 1.1 20 0 40 ‐2.09 Basal only
GNB1;GNB2;GNB3 P62879;P62873;P16520 328‐337 ATGSW(+3.99)DSFLK A*03:01 221.6 1.6 40 0 20 ‐2.21 Basal only
GPR162 Q16538 32‐41 AW(+15.99)IILSISAK A*03:01 3880.6 0.2 100 100 40 1.24 2.03
HAUS7 Q99871 196‐203 PLDM(+15.99)QPLL A*02:01 3427.1 0.4 0 60 0 Not detected IFN‐γ/TNF‐α/IL‐1β only
HID1 Q8IV36 752‐760 GTAM(+15.99)WFRTY A*03:01 1730.8 0.2 20 40 20 ‐0.76 0.70
HLA‐B P30488;P30487;P30483;P30466 326‐334 VVATVM(+15.99)CRR A*03:01 766.3 0.6 0 40 40 Basal only ‐1.00
HSF2 Q03933 156‐164 SLW(+3.99)KEVSEL A*02:01 30.3 1.9 40 80 40 ‐0.06 0.21
HSP90AA1;HSP90AA2P;HSP90AB1;HSP90AB2P P08238;Q14568;Q58FF8;P07900 19‐27 AEIAQLM(+15.99)SL B*40:01 8.2 2.4 40 0 20 1.92 Basal only
HSPA14 Q0VDF9 56‐66 RIRNISNTVM(+15.99)K A*03:01 44.3 6.0 40 0 40 0.66 Basal only
HSPA4;HSPA4L O95757;P34932 169‐177 RLM(+15.99)NETTAV A*02:01 7.3 27.5 80 100 40 0.49 0.18
IFI6 P09912 45‐53 M(+15.99)AVGGGLAV C*03:04 6.3 0.3 40 0 0 IFN‐γ only Not detected
IRAK2 O43187 604‐612 KLM(+15.99)ENILLY A*03:01 28.9 0.9 60 80 20 2.76 0.78
IRF6 O14896 235‐243 KEYGQTM(+15.99)TV B*40:01, B*49:01 99.7, 81.9 1.4, 2.0 20 20 40 ‐1.07 ‐2.56
KPNA1;KPNA5;KPNA6 O60684;P52294;O15131 432‐440 VM(+15.99)DSKIVQV A*02:01 9.7 4.3 20 60 40 0.66 0.16
KRT19 P08727;P08727 361‐369 QEYQRLM(+15.99)DI B*49:01 120.8 0.8 40 20 0 IFN‐γ only IFN‐γ/TNF‐α/IL‐1β only
MADD Q8WXG6 389‐397 KM(+15.99)PDDVWLV A*02:01 2.7 9.8 40 80 40 1.07 0.80
MED19 A0JLT2 164‐172 RLM(+15.99)HIQPPK A*03:01 14.3 29.2 20 40 0 IFN‐γ only IFN‐γ/TNF‐α/IL‐1β only
MKI67 P46013 540‐549 VM(+15.99)HTPPVLKK A*03:01 17.5 2.7 20 40 20 1.49 1.02
MTOR P42345 1189‐1197 QIFIPM(+15.99)VNK A*03:01 61.5 0.7 40 40 20 2.39 ‐0.39
NAA20 P61599 91‐99 KLM(+15.99)ELLEEI A*02:01 2.2 51.5 40 0 20 1.65 Basal only
NDN Q99608 161‐169 HTM(+15.99)EFALVK A*03:01 44.1 2.5 0 40 0 Not detected IFN‐γ/TNF‐α/IL‐1β only
NOMO1;NOMO2;NOMO3 Q15155;P69849;Q5JPE7 1067‐1075 SEYLPTLW(+3.99)V B*40:01, B*49:01 332.6, 132.9 0.7, 0.7 40 60 40 0.48 ‐0.62
NRIP1 P48552 745‐753 ALSEQILM(+15.99)V A*02:01 5.9 12.1 100 40 0 IFN‐γ only IFN‐γ/TNF‐α/IL‐1β only
OSBPL9 Q96SU4 138‐147 KLFDDKLQNC(+47.98) A*02:01 188.0 1.5 40 100 40 3.08 0.57
PARP14 Q460N5 278‐288 KVLDTIM(+15.99)ATKL A*02:01 212.1 1.3 40 0 0 IFN‐γ only Not detected
PCNA P12004 197‐205 IEM(+15.99)NEPVQL B*40:01 24.5 2.3 60 60 40 0.79 0.15
PCNA P12004 117‐126 KLM(+15.99)DLDVEQL A*02:01 5.3 8.8 40 0 20 2.59 Basal only
PCSK9 Q8NBP7 194‐202 REIEGRVM(+15.99)V B*40:01 14.2 1.7 60 0 20 1.47 Basal only
PKLR;PKM P14618;P30613 21‐29 AM(+15.99)ADTFLEH A*03:01 365.9 1.0 0 40 0 Not detected IFN‐γ/TNF‐α/IL‐1β only
PLXNA4 Q9HCM2 1538‐1547 KNVPC(+47.98)SHRPK NA NA NA 0 0 40 Basal only Basal only
POMP Q9Y244 124‐132 SEVM(+15.99)GEPHL B*40:01 17.9 1.1 100 100 40 1.30 0.02
PRKAR1A;PRKAR1B P10644;P31321 244‐253 KM(+15.99)YEEFLSKV A*02:01 3.4 10.1 40 0 0 IFN‐γ only Not detected
PRKDC P78527 1302‐1311 AM(+15.99)HDIIAAEK A*03:01 69.1 4.6 20 0 60 ‐2.66 Basal only
PSMA2 P25787 113‐121 RVASVM(+15.99)QEY A*03:01 553.4 0.6 20 60 20 0.29 0.84
PSMB9 P28065 15‐24 GEVHTGTTIM(+15.99) B*40:01 40.3 1.1 100 0 0 IFN‐γ only Not detected
RASSF6 Q6ZTQ3 184‐194 RTM(+15.99)SEAALVRK A*03:01 44.2 17.1 0 40 40 Basal only ‐0.75
REC8 O95072 199‐207 AEPIRM(+15.99)LEI NA NA NA 100 100 20 5.38 4.26
RPAIN Q86UA6 128‐136 AEW(+3.99)EANPLI B*40:01, B*49:01 20.1, 35.5 1.2, 1.2 20 40 20 ‐1.83 ‐1.16
RPL19 P84098 137‐145 ILM(+15.99)EHIHKL A*02:01 2.4 39.3 40 20 20 1.00 ‐1.98
RPL3 P39023 324‐333 GEVTNDFVM(+15.99)L B*40:01 16.1 1.2 100 0 0 IFN‐γ only Not detected
RPN2 P04844 619‐627 RM(+15.99)LAQQAVK A*03:01 31.4 4.4 40 40 20 1.13 ‐0.73
RPS29 P62273 5‐13 QLYW(+15.99)SH(+15.99)PRK A*03:01 14.3 2.2 0 20 40 Basal only ‐1.12
SEC11C Q9BY50 180‐189 AVM(+15.99)GAYVLLK A*03:01 26.3 12.2 40 80 60 ‐0.57 ‐0.66
SEC11C Q9BY50 24‐32 KM(+15.99)NKRQLYY A*03:01 11.9 1.5 80 80 20 1.65 0.04
SEC14L1 Q92503 593‐601 QLIDKVW(+3.99)QL A*02:01 3.9 5.2 0 40 20 Basal only ‐0.50
SELT P62341 32‐42 KM(+15.99)QYATGPLLK A*03:01 25.1 7.6 20 60 40 ‐0.75 ‐0.66
SEPT9 Q9UHD8 492‐500 REM(+15.99)IPFAVV B*40:01 17.8 1.7 40 40 0 IFN‐γ only IFN‐γ/TNF‐α/IL‐1β only
SKA2 Q8WVK7 3‐11 AEVDKLELM(+15.99) B*40:01 121.2 1.0 100 100 20 4.21 3.13
SLC25A3 Q00325 226‐234 RQIPYTM(+15.99)M(+15.99)K A*03:01 38.2 14.0 40 40 40 1.51 ‐0.82
SMCHD1 A6NHR9 393‐402 REIQDDM(+15.99)QTL B*40:01 8.9 1.4 0 20 40 Basal only ‐2.08
SSRP1 Q08945 316‐324 RVM(+15.99)KALVNR A*03:01 251.0 3.6 80 20 20 2.07 ‐1.51
STAT1 P42224 300‐308 VLW(+3.99)DRTFSL A*02:01 3.5 8.3 20 40 0 IFN‐γ only IFN‐γ/TNF‐α/IL‐1β only
STAU1 O95793 416‐424 GILPM(+15.99)VPEV A*02:01 8.3 7.2 20 0 40 ‐3.26 Basal only
STIP1 P31948 252‐262 KELDPTNM(+15.99)TYI B*40:01, B*49:01 125.7, 135.9 0.9, 0.9 60 40 20 4.21 1.40
TBCK Q8TEA7 123‐131 LLDRKGH(+15.99)IK A*03:01 840.8 0.6 0 0 40 Basal only Basal only
TGM6 O95932 617‐626 M(+15.99)VGVAVTVEV A*02:01 171.4 1.0 40 20 20 ‐0.42 ‐0.17
THOC7 Q6I9Y2 76‐84 REM(+15.99)ENYEKI B*40:01, B*49:01 22.7, 92.7 1.0, 1.4 40 60 40 ‐0.35 ‐0.89
TIMM23;TIMM23B O14925;Q5SRD1 161‐169 GTMTGM(+15.99)LYK A*03:01 16.2 9.9 20 20 40 ‐0.44 ‐0.65
TJP2 Q9UDY2 80‐88 QENDRVVM(+15.99)V B*49:01 378.0 0.6 40 0 0 IFN‐γ only Not detected
TM9SF2 Q99805 545‐553 SIWSHQM(+15.99)YY A*03:01 48.8 0.4 20 40 40 ‐0.33 ‐0.47
TMED9 Q9BVK6 130‐139 SLFAGGM(+15.99)LRV A*02:01 9.9 6.0 40 0 20 1.40 Basal only
TNPO2 O14787 215‐223 IEH(+15.99)LFALAV B*40:01, B*49:01 58.2, 101.9 1.2, 0.9 20 40 20 1.94 0.15
TOP2A;TOP2B P11388;Q02880 168‐177 KLC(+47.98)NIFSTKF NA NA NA 40 0 0 IFN‐γ only Not detected
TRANK1 O15050 1987‐1996 EAH(+15.99)FLQGVIL NA NA NA 100 100 40 1.90 1.48
TTF1 Q15361 809‐817 AVYVPFW(+3.99)QK A*03:01 25.6 2.5 40 60 20 0.19 ‐0.21
UBL5 Q9BZL1 60‐68 YEIHDGM(+15.99)NL B*40:01 13.6 1.2 40 0 0 IFN‐γ only Not detected
UBR2 Q8IWV8 703‐711 SM(+15.99)M(+15.99)DPNHFL A*02:01 3.6 5.7 40 0 0 IFN‐γ only Not detected
UQCRQ O14949 3‐11 REFGNLTRM(+15.99) B*40:01 33.0 1.7 80 100 40 1.76 ‐0.10
USP11 P51784 611‐619 M(+15.99)LFGHPLLV A*02:01 3.1 7.9 20 20 40 2.22 ‐1.23
USP33 Q8TEY7 621‐629 HELM(+15.99)FSTKI B*40:01, B*49:01 91.6, 113.6 1.0, 0.9 40 20 0 IFN‐γ only IFN‐γ/TNF‐α/IL‐1β only
UTRN P46939 414‐422 RLHDVLM(+15.99)EL A*02:01 5.8 11.7 40 40 40 1.06 ‐0.44
UTRN P46939 1340‐1349 RETDQM(+15.99)LQVL B*40:01 10.0 2.1 40 20 20 ‐0.41 ‐1.69
 
Table S2. Related to Fig 1G. 
List of the 99 HLA-I-bound 
PTM peptides originating 
from ubiquitous proteins 
identified in ECN90 β cells. 
Data representation is the same 
as in Table S1. NetMHCstabpan 
predicted affinity and stability 
scores refer to the unmodified aa 
sequence. 
 
Table S3. Related to Fig 2F. List of the 33 HLA-I-bound peptides identified in primary human islets. The same bioinformatics filters used for 
ECN90 β cells (Fig. 1G) were applied, barring the inter-sample reproducibility and HLA-I enrichment filters due to the analysis of a single split islet 
preparation (cytokine-treated or not), without mock immunopurification. Aa sequences are listed according to the number of peptides identified for 
each source protein. HLA-I restrictions were assigned based on the predicted affinity and stability (NetMHCstabpan). The last column displays the 
log2 median FC in peptide content for the IFN-γ/TNF-α/IL-1β vs. basal condition (color codes as in Table S1). Source proteins and/or peptides 
previously identified or not in ECN90 β cells are in blue and red, respectively, with peptide length variants marked with an asterisk. The 3 HLA-A2-
restricted peptides retained for CD8+ T-cell studies are highlighted in yellow: a SCG5186-195 shorter variant with a higher affinity than the previously 
identified SCG5186-196 peptide, a newly identified CHGB440-448 peptide and an IAPP15-17/IAPP5-10 or PTPRN596-598/IAPP5-10 peptide splice aa sequence 
(VAL/KLQVFL) previously identified in ECN90 β cells, which was finally assigned an HLA-A2 restriction based on the HLA-I haplotype of the islet 
preparation (HLA-A*02:01/25:01, -B*39:01/51:01, -C*12:03/14:02, i.e. sharing only HLA-A2 with ECN90 β cells).  NA, not available. 
Source protein(s) Accession number(s) Aminoacid positions Sequence HLA restriction Predicted affinity (nM) Predicted stability (h) IFN‐γ/TNF‐α/IL‐1β log2 FC
2‐10 ALWMRLLPL A*02:01 26.7 5.6 Basal only
2‐12* ALWMRLLPLLA A*02:01 83.8 2.8 ‐2.16
5‐13 MRLLPLLAL B*39:01 71.4 0.6 1.71
5‐13 M(+16)RLLPLLAL B*39:01 71.4 0.6 Basal only
15‐24 ALWGPDPAAA A*02:01 95.5 1.8 ‐3.26
15‐24 ALW(+16)GPDPAAA A*02:01 95.5 1.8 ‐3.58
15‐24 ALW(+4)GPDPAAA A*02:01 95.5 1.8 Basal only
17‐24* WGPDPAAA NA NA NA ‐3.87
29‐38 HLCGSHLVEA A*02:01 521.1 1.5 6.64
33‐41 SHLVEALYL B*39:01 283.8 0.4 IFN‐γ/TNF‐α/IL‐1β only
34‐42 HLVEALYLV A*02:01 3.3 17.8 Basal only
57‐67* EAEDLQVGQVE NA NA NA 0.13
344‐352 KMDQLAKEL A*02:01 543.8 0.6 0.04
344‐354 KMDQLAKELTA A*02:01 823.2 0.6 ‐1.68
381‐390 YGFRGPGPQL C*12:03, C*14:02 150.2, 139.9 0.2, 0.2 ‐0.37
383‐390 FRGPGPQL B*39:01 380.7 0.7 ‐0.90
791‐800 DQKNGATHYW NA NA NA ‐1.08
1058‐1066 EVTKSFIEY A*25:01 370.6 1.3 ‐1.86
1319‐1327 NRVTGVYEL B*39:01 19.8 0.7 ‐0.72
136‐144 DTAEFSREF A*25:01 187.4 0.7 4.61
186‐195* YLQGQRLDNV A*02:01 44.8 2.2 1.77
186‐196 YLQGQRLDNVV A*02:01 151.8 1.7 ‐1.19
429‐437 YFMSDTREE C*14:02 1857.7 0.1 Basal only
429‐437 YFM(+16)SDTREE C*14:02 1857.7 0.1 IFN‐γ/TNF‐α/IL‐1β only
440‐448 FLGEGHHRV A*02:01 4.4 8.6 ‐3.35
PCSK2 (n=1) P16519 26‐34 ERPVFTNHF C*14:02 3731.5 0.1 0.74
IAPP (n=1) P10997 23‐30 TPIESHQV B*51:01 1423.2 1.1 1.84
SLC7A2 (n=1) P52569 650‐658 IFHEKTSEF C*14:02 27.4 0.3 0.33
UNC13A (n=1) Q9UPW8 1234‐1243 DIISKDFASY A*25:01 73.9 0.8 ‐0.58
IAPP/IAPP;PTPRN/IAPP P10997/P10997;Q16849/P10997 15‐17/5‐10;596‐598/5‐10 VAL/KLQVFL A*02:01, C*12:03 3599.1, 3763.0 0.5, 0.1  ‐0.58
SCG5/PCSK2;SLC30A8/PCSK2 P05408/P16519;Q8IWU4/P16519 113‐115/565‐570;168‐170/565‐570 YPD/RGTWTL B*39:01 10.0 0.8 IFN‐γ/TNF‐α/IL‐1β only
PTPRN/IAPP Q16849/P10997 795‐802/44‐48 WQM(+16)VWESG/RLANF B*39:01, C*14:02 1487.1, 1801.9 0.3, 0.2  1.84



















GADA IA-2A ZnT8A Therapy 
Screening Healthy (n=14) 
H004N 44 M NA NA NA NA NA 
H005N 36 F NA NA NA NA NA 
H017N 35 F NA NA NA NA NA 
H079O 36 F NA NA NA NA NA 
H087N 34 M NA NA NA NA NA 
H106S 47 F NA NA NA NA NA 
H297S 28 M NA NA NA NA NA 
H312C 36 M NA NA NA NA NA 
H314C 26 M NA NA NA NA NA 
H315C 43 F NA NA NA NA NA 
H316C 27 F NA NA NA NA NA 
H354C 26 F NA NA NA NA NA 
H356C 28 M NA NA NA NA NA 
H372C 24 F NA NA NA NA NA 
      34.5 43% M           




D216P 27 M 10.9 + - - Insulin 
D217Db 34 M 19.0 + NA NA Insulin 
L264D 28 F 32.0 + + + Insulin 
D267T 25 F 1.0 + NA NA Insulin 
D287T 30 M 4.1 + NA NA Insulin 
D314D 44 F 0.6 + + + Insulin 
D324D 28 F 11.3 + + NA Insulin 
D325D 19 M 0.3 - - + Insulin 
D327V 34 F 0.7 + - NA Insulin 
D339V 29 M 0.4 + + NA Insulin 
    28.5 50% M 2.6         
    (19-44) 50% F (0.3-32.0)         
Healthy 
(n=10) 
H015T 30 M NA NA NA NA NA 
H170S 34 F NA NA NA NA NA 
H172O 33 F NA NA NA NA NA 
H192C 25 F NA NA NA NA NA 
H193C 45 F NA NA NA NA NA 
H227C 26 M NA NA NA NA NA 
H230C 29 F NA NA NA NA NA 
H245C 22 M NA NA NA NA NA 
H314C 26 M NA NA NA NA NA 
H354C 26 F NA NA NA NA NA 
      27.5 40% M           
      (22-45) 60% F           
 
Table S4. Related to Fig. 4-5. Characteristics of HLA-A2+ study subjects for ex-vivo 
MMr studies on PBMCs. The healthy donors analyzed in Fig. 4 (screening phase) and the 
T1D and age/sex-matched healthy donors analyzed in Fig. 5 (validation phase) are listed. The 
distribution of age, gender and T1D duration is shown at the bottom of each list (median and 
range for numerical variables). GADA, IA-2A, ZnT8A, anti-GAD, -IA-2 and -ZnT8 aAbs, 















 Pancreas MMr+  PLN MMr+ 






6070 F 23 7 IA-2/mIAA <0.05   39 74 0   32 0  
6161 F 19 7 IA-2/mIAA <0.05 110 59  124 0 0 0  1176 0 
6211 F 24 4 GAD/IA-2/ZnT8/mIAA <0.05 29 32  30 0 103 45  60 54 
6212 M 20 5 mIAA <0.05 19 29  0  0 0  0  
6237 F 18 12 GAD/mIAA <0.05   8 267 0   0 0  
6242 M 39 19 IA-2/mIAA <0.05 33 9  66 0 0 0  101 0 
6243 M 13 5 mIAA 0.42 47 17  0  72 34  209 0 
6258 F 39 37 mIAA <0.05   19 118 0   0 299 0 






6080 F 69 NA GAD/mIAA 1.84 38 39  55 25 43 41  50 61 
6101 M 65 NA GAD 26.18 36 30  0  0 0  0  
6123 F 23 NA GAD 2.01 22 48  0  0 0  0  
6151 M 30 NA GAD 5.49   9 28 0      
6154 F 49 NA GAD <0.05   21 64 0      
6171 F 4 NA GAD 8.95 13 9  37 0 0 0  0  
6347 M 9 NA mIAA 3.26 15 7  33 0 66 60  60 191 
6388 F 25 NA GAD/mIAA 1.38   0 34 0   0 35 0 











6103 M 2 NA — 0.98   0 55 0   0 0  
6174 M 21 NA — 3.00 0 0    28 0    
6179 F 20 NA — 2.74   0 96 0   67 150 0 
6182 M 3 NA — 2.28   4 23 0   89 163 65 
6227 F 17 NA — 2.75   18 3 0   0 0  
6234 F 20 NA — 6.89   0 6 0   0 0  
6254 M 38 NA — 6.43 0 0  0  0   0  
6271 M 17 NA — 11.47 0 5  0  0 0  0 0 
6287 F 57 NA — 4.75 7 8  4 0 0 0  0  
6289 M 19 NA — 8.05 0 6  0  55 0  0  
6357 M 5 NA — 8.82 9 29  0  32 0  0  






6028 M 33 17 — 22.40  25  0   0  0  
6059 F 19 0.3 — 10.68 12   0  0   107 0 
6273 F 45 2 — 3.17 13 7    0 0    
6275 M 48 2 — 3.46 0   0  133 117  0  
 
Table S5. Related to Fig. 6. nPOD cases analyzed by in-situ tissue MMr staining. The clinical characteristics 
of each case are reported along with the counts (x10‒3) of MMr+ cells/mm2 pancreas and PLN section area for 
each of the indicated peptides. Positive sections are marked in red. Case #6287 (presenting a circumscribed 
neuroendocrine tumor in the pancreatic pan-body region; pan-tail region analyzed here) was classified as a non-




Table S6. Related to STAR Methods. Configuration of the flow cytometer used for 
HLA-A2 MMr assays. L/D, Live/Dead. 
 
 
Lasers and filters Photomultiplier tubes (PMTs) 
488 nm blue laser C B A       
Long pass (LP) filter \ 502 655       
Band pass (BP) filter 488/10 530/30 695/40       
Fluorochrome SSC FITC         
561 nm yellow-green laser E D C B A   
Long pass (LP) filter \ 600 635 685 735   
Band pass (BP) filter 582/15 610/20 660/20 710/50 780/60   
Fluorochrome PE PE-CF594     PE-Cy7   
633 nm red laser C B A       
Long pass (LP) filter \ 710 750       
Band pass (BP) filter 660/20 730/45 780/60       
Fluorochrome APC   APC-H7       
405 nm violet laser F E D C B A 
Long pass (LP) filter \ 502 595 630 675 750 
Band pass (BP) filter 450/50 525/50 605/20 655/8 710/50 780/60 
Fluorochrome BV421 L/D Aqua   BV650 BV711 BV786 
